



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 204874

TO: Gerald R Ewoldt
Location: rem/3C83/3C70
Art Unit: 1644
Friday, October 20, 2006
Case Serial Number: 10/620621

From: John DiNatale
Location: Biotech-Chem Library
REM-1B65
Phone: (571)272-2557
john.dinatale@uspto.gov

Search Notes

Examiner Ewoldt,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

John DiNatale
Technical Information Specialist
STIC Biotech/Chem Library
(571)272-2557

77452

STIC-Biotech/ChemLib

10-755

204874

From: Chan, Christina
Sent: Tuesday, October 17, 2006 5:38 PM
To: Ewoldt, Gerald; STIC-Biotech/ChemLib
Subject: RE: RUSH Seq Search for 10/620,621

Please rush. Thanks Chris

Chris Chan
TC 1600 New Hire Training Coordinator and SPE 1644
(571)-272-0841
Remsen, 3E89

-----Original Message-----

From: Ewoldt, Gerald
Sent: Tuesday, October 17, 2006 5:22 PM
To: Chan, Christina
Subject: RUSH Seq Search for 10/620,621

Christina,
Please authorize a RUSH Search.

STIC,
Please search SEQ ID NOS:1-10 including interference and send paper copy.

Thanks,

G.R. Ewoldt, Ph.D.
Primary Examiner
Remsen Bldg., 3C83
571-272-0843

1644
3C80

1 aa 20
2 20
3 20
4 19
5 18
6 aa 20
7 aa 20
8 20
9 19
10 aa 18

entered
10/18

M9

Searcher: _____
Searcher Phone: _____
Date Searcher Picked up: _____
Date completed: _____
Searcher Prep Time: _____
Online Time: _____

Type of Search
NA# _____ AA#: _____
S/L: _____ Oligomer: _____
Encode/Transl: _____
Structure #: _____ Text: _____
Inventor: _____ Litigation: _____

Vendors and cost where applicable
STN: _____
DIALOG: _____
QUESTEL/ORBIT: _____
LEXIS/NEXIS: _____
SEQUENCE SYSTEM: _____
WWW/Internet: _____
Other (Specify): _____



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact **the searcher or contact:**

Mary Hale, Information Branch Supervisor
571-272-2507 Remsen 1 A51

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* Example: 1610
- *Relevant prior art found, search results used as follows:*
- 102 rejection
 - 103 rejection
 - Cited as being of interest.
 - Helped examiner better understand the invention.
 - Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- Foreign Patent(s)
- Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ *Relevant prior art not found:*

- Results verified the lack of relevant prior art (helped determine patentability).
- Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library, Remsen Bldg.



Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: October 18, 2006, 19:10:59 ; Search time 93.299 Seconds
(without alignments)

Title: US-10-620-621-1

Perfect score: 85

Sequence: 1 TGYYXXXXQSPEKSLIEWIG 20

Scoring table: BLASTM62

Gapop 10.0 , Gapext 0.5

Searched: 2589679 seqs, 457216429 residues

Total number of hits satisfying chosen parameters: 2589679

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_8:*

1: geneseqP1980s:*

2: geneseqP1990s:*

3: geneseqP2000s:*

4: geneseqP2001s:*

5: geneseqP2002s:*

6: geneseqP2003as:*

7: geneseqP2003bs:*

8: geneseqP2004s:*

9: geneseqP2005s:*

10: geneseqP2006s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution:

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	80	94.1	20	AAW05029	Aaw05029 Synthetic
2	80	94.1	20	8 ADR14727	Adr14727 Amino aci
3	79	92.9	20	5 AAW05034	Aaw05034 Synthetic
4	79	92.9	20	5 AAB27944	Aae27944 Murine 5G
5	79	92.9	20	8 ADT0140	Adf0140 Anti-idiotype
6	79	92.9	20	8 ADR14717	Adr14717 Synthetic
7	79	92.9	470	8 ADM72027	Adm72027 Chimeric
8	79	92.9	470	10 AEF5093	Aef5093 Variable
9	71	83.5	255	7 ABP45615	Abp45615 Human Bly
10	71	83.5	255	7 ADG96442	Adg96442 Single ch
11	71	83.5	255	9 AED78435	Aed78435 Human B L
12	71	83.5	467	9 ADZ51037	Adz51037 Amino aci
13	71	83.5	470	9 ADZ51043	Adz51043 Amino aci
14	70	82.4	97	7 ADD28121	Add28121 Lymphoma
15	68	80.0	672	6 ABP58454	Abp58454 Engineere
16	68	80.0	672	10 AEF80925	Aef80925 Staphyloc
17	65	76.5	129	5 AAU81215	Aau81215 Human trk
18	64	75.3	123	6 ABR55799	Abr55799 Heavy Cha
19	64	75.3	123	6 ABR55823	Abr55823 Heavy Cha
20	64	75.3	124	6 ADY96947	Ady96947 Human imm
21	64	75.3	125	9 ADZ41992	Adz41992 Ig H chia
22	64	75.3	255	5 ABP45621	Abp45621 Human Bly
23	64	75.3	255	7 ADG96458	Adg96458 Single ch

RESULT 1

AAW05029
ID AAW05029 standard; peptide; 20 AA.
XX
AC AAW05029;
XX DT 29-MAY-1997 (first entry)
XX DE Synthetic peptide for treating systemic lupus erythematosus.
XX KW SLE; systemic lupus erythematosus; autoimmune disease; monoclonal; anti-DNA antibody; CDR; complementarity determining region; 16/6 id; idiotype; nuclear antigen.
XX OS Synthetic.

ALIGNMENTS

Human B L
Aay64660 Human 5'
Aay64660 Human inc
Add72224 Signal pe
Add73215 Lymphoma
Aar79244 Heavy cha
Aab50793 Murine an
Aea34944 Human ant
Acb1785 Ephi2-spe
Aef10097 Mouse-hum
Aef10112 Mouse-hum
Aae03752 Murine PS
Adh44153 Human ant
Ab21865 Human DC-
Aeb21868 Human DC-
Aeb21864 Human DC-
Aeb21869 Human DC-
Aeb21863 Human DC-
Aay87655 Murine PI
Abu08927 Mouse amy
Aay64689 Human 5'

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	80	94.1	20	2 AAW05029	Aaw05029 Synthetic
2	80	94.1	20	8 ADR14727	Adr14727 Amino aci
3	79	92.9	20	5 AAW05034	Aaw05034 Synthetic
4	79	92.9	20	5 AAB27944	Aae27944 Murine 5G
5	79	92.9	20	8 ADT0140	Adf0140 Anti-idiotype
6	79	92.9	20	8 ADR14717	Adr14717 Synthetic
7	79	92.9	470	8 ADM72027	Adm72027 Chimeric
8	79	92.9	470	10 AEF5093	Aef5093 Variable
9	71	83.5	255	7 ABP45615	Abp45615 Human Bly
10	71	83.5	255	7 ADG96442	Adg96442 Single ch
11	71	83.5	255	9 AED78435	Aed78435 Human B L
12	71	83.5	467	9 ADZ51037	Adz51037 Amino aci
13	71	83.5	470	9 ADZ51043	Adz51043 Amino aci
14	70	82.4	97	7 ADD28121	Add28121 Lymphoma
15	68	80.0	672	6 ABP58454	Abp58454 Engineere
16	68	80.0	672	10 AEF80925	Aef80925 Staphyloc
17	65	76.5	129	5 AAU81215	Aau81215 Human trk
18	64	75.3	123	6 ABR55799	Abr55799 Heavy Cha
19	64	75.3	123	6 ABR55823	Abr55823 Heavy Cha
20	64	75.3	124	6 ADY96947	Ady96947 Human imm
21	64	75.3	125	9 ADZ41992	Adz41992 Ig H chia
22	64	75.3	255	5 ABP45621	Abp45621 Human Bly
23	64	75.3	255	7 ADG96458	Adg96458 Single ch

New synthetic peptide(s) for treating systemic lupus erythematosus - based on complementarity determining region of pathogenic anti-DNA monoclonal antibody that induces SLE-like disease in mice.

XX Claim 3; Page 36; 51pp; English.
 XX
 PS AAW05029-W05038 are synthetic peptides based on the complementarity-
 XX determining region (CDR) of the heavy or light chain of a pathogenic 16/6
 CC Id anti-DNA monoclonal antibody that induces a systemic lupus
 CC erythematosus (SLE)-like disease response in mice. The peptides and their
 CC derivatives are used for treating SLE. The peptides inhibit or suppress
 CC specific antigen responses of SLE patients without affecting all other
 CC immune responses
 XX Sequence 20 AA;
 SQ Query Match 94.1%; Score 80; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 6.9e-07;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 TGYYXXXXXQSPEKSLEWIG 20
 Db 1 TGYYXXXXXQSPEKSLEWIG 20

RESULT 2
 ADR14727
 ID ADR14727 standard; peptide; 20 AA.
 XX
 AC ADR14727;
 XX 21-OCT-2004 (first entry)
 DT XX
 DE Amino acid sequence of a peptide used to treat SLE.
 XX
 complementarity determining region; CDR: heavy chain: light chain;
 KW monoclonal anti-DNA 16/6 idiotype antibody; 16/6 Id antibody;
 KW anti-DNA antibody; induces systemic lupus erythematosus; SLE.
 XX
 OS Synthetic.
 XX
 FH Key : Location/Qualifiers
 FT Misc-difference 5
 FT /label= Met, Ala, Val
 FT Misc-difference 6
 FT /label= Gln, Asp, Glu, Arg
 FT Misc-difference 7
 FT /label= Trp, Ala
 FT Misc-difference 8
 FT /label= Val, Ser
 FT Misc-difference 9
 FT /label= Lys, Glu, Ala
 XX WO2004064787-A2.
 XX
 PD 05-AUG-2004.
 XX
 PP 14-JAN-2004; 2004WO-US000948.
 PR 14-JAN-2003; 2003US-0439318P.
 XX
 PA (TEVA-) TEVA PHARM IND LTD.
 PA (TEVA-) TEVA PHARM USA INC.
 PI Cohen-Vered S, Naftali E, Weinstein V, Gilbert A, Klinger E;
 XX WPI: 2004-580636/56.
 XX
 PT Pharmaceutical composition for treating systemic lupus erythematosus
 PT (SLE), has salt of peptide corresponding to complementarity-determining
 PT region of heavy/light chain of anti-DNA 16/6 Id antibody that induces
 PT immune response to SLE.
 XX
 PS Claim 1: SEQ ID NO 11; 132pp; English.
 XX
 CC The specification describes a pharmaceutical composition, comprising a

CC salt of a peptide with 12-30 consecutive amino acids having a sequence
 CC corresponding to an amino acid sequence found within complementarity-
 CC determining region (CDR) of the heavy or light chain of the human
 CC monoclonal anti-DNA 16/6 idiotype (16/6 Id) antibody, or a heavy or light
 CC chain of a pathogenic anti-DNA monoclonal antibody that induces systemic
 CC lupus erythematosus (SLE)-like disease response in mice. The composition
 CC is useful for treating SLE and for alleviating symptoms of SLE in a human
 CC derivative. The present sequence represents a peptide which is used in
 CC pharmaceutical compositions of the invention.
 XX
 Sequence 20 AA;
 SQ

Query Match 94.1%; Score 80; DB 8; Length 20;
 Best Local Similarity 100.0%; Pred. No. 6.9e-07;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 TGYYXXXXXQSPEKSLEWIG 20
 Db 1 TGYYXXXXXQSPEKSLEWIG 20

RESULT 3
 AAW05034
 ID AAW05034 standard; peptide; 20 AA.
 XX
 AC AAW05034;
 XX 29-MAY-1997 (first entry)
 DT XX
 DE Synthetic peptide for treating systemic lupus erythematosus.
 XX
 SLB; systemic lupus erythematosus; autoimmune disease; monoclonal;
 KW anti-DNA antibody; CDR; complementarity determining region; 16/6 Id;
 KW idiotype; nuclear antigen.
 XX
 OS Synthetic.
 XX WO9630057-A1.
 PN XX
 PD 03-OCT-1996.
 XX
 PP 27-MAR-1996; 96WO-US004206.
 XX
 PR 28-MAR-1995; 95IL-00113159.
 XX
 PA (YEDA) YEDA RES & DEV CO LTD.
 PA (RYCU/) RYCUS A.
 XX
 PI Mozes E, Waisman A;
 XX DR 1996-455014/45.
 XX
 New synthetic peptide(s) for treating systemic lupus erythematosus -
 PT based on complementarity determining region of pathogenic anti-DNA
 PT monoclonal antibody that induces SLE-like disease in mice.
 XX
 PS Claim 4; Page 37; 51pp; English.
 XX
 AAW05029-W05038 are synthetic peptides based on the complementarity-
 CC determining region (CDR) of the heavy or light chain of a pathogenic 16/6
 CC Id anti-DNA monoclonal antibody (MAB), that induces a systemic lupus
 CC erythematosus (SLE)-like disease in mice. The peptides and their
 CC derivatives are used for treating SLE. The peptides inhibit or suppress
 CC specific antigen responses of SLE patients without affecting all other
 CC immune responses
 XX
 Sequence 20 AA;
 SQ

Query Match 92.9%; Score 79; DB 2; Length 20;
 Best Local Similarity 75.0%; Pred. No. 1e-06;
 Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 CC
 Qy 1 TGYYXXXXXQSPEKSLEWIG 20

Db ||||| TGYMMQWVKQSPEKSLEWIG 20

RESULT 4
AAE27944
ID AAE27944 standard; peptide; 20 AA.

AC AAE27944;

XX 27-DEC-2002 (first entry)

DE Murine 5G12 mAb VH chain CDR1 based peptide.

XX Complementarity-determining region; CDR; variable heavy chain; VH; VL;

KW variable light chain; SLE-associated response; immunosuppressive; SLE;

KW systemic lupus erythematosus; dermatological; therapy; antiinflammatory;

KW mouse.

XX OS Mus sp.

XX PN WO200267848-A2.

XX PD 06-SEP-2002.

XX PT 26-FEB-2002; 2002WO-IL0000148.

XX PR 26-FEB-2001; 2001IL-00141647.

XX PA (YEDA) YEDA RES & DEV CO LTD.

XX XX Mozes E;

XX DR WPI; 2002-698624/75.

XX PD 04-DEC-2003.

XX PF 22-MAY-2003;

XX PR 28-MAY-2002; 2002US-0383136P.

XX (OMRI-) OMRIX BIOPHARMACEUTICALS INC.

XX OS Nur I, Shoanfeld Y;

XX PN WO2003099868-A2.

XX DR WPI; 2004-042771/04.

XX PD 04-DEC-2003.

XX PT Identifying molecules, which mimic an idiotype of an autoimmune disease-associated autoantibody, useful for treating an autoimmune disease, e.g. myasthenia gravis, comprises the use of immunoglobulins purified from pooled plasma.

XX PT Example 3; Page 12; 43pp; English.

XX XX The present invention describes a method (M1) for identifying molecules CC (I) which mimic an idiotype of an autoimmune disease-associated CC autoantibody (autoantibodies). M1 comprises purifying autoantibodies from CC sera of one or more patients afflicted with the autoimmune disease,

CC binding the autoantibodies to a solid phase to form an affinity matrix,

CC contacting pooled plasma or B cells comprising immunoglobulins with the

CC affinity matrix followed by removal of unbound plasma components, eluting

CC bound immunoglobulins, being anti-idiotypic antibodies (anti-Id) to

CC autoantibodies, from the matrix, providing a molecular library comprising

CC several molecule members, and contacting the anti-Id with the molecular

CC library and isolating the bound molecules, which are bound by the anti-

CC Id, the bound molecules being molecules that mimic an idiotype of

CC the autoantibodies. (I) have immunosuppressive, antiinflammatory,

CC dermatological, muscular, neuroprotective, CNS, anti-HIV, nootropic,

CC neuroleptic, antithyroid, thyromimetic, antidiabetic, anabolic,

CC hyperactive, endocrine, antisporotic, hepatotropic, virucide,

CC antianæmic, haemostatic, gastrointestinal, antiulcer, antiinflammtory,

CC anti rheumatic, antiarthritic, nephrotropic, antiarteriosclerotic,

CC cardiant, ophthalmological, uropathic and antipyretic activities, and can

CC be used in vaccines. The molecules (I), anti-Id and pharmaceutical

CC compositions of the present invention can be used for treating a patient

CC afflicted with an autoimmune disease. The molecules (I) are also useful

CC for screening chemical compounds for their potential use in treating an

CC autoimmune disease. The present sequence is given in the exemplification

XX SQ Sequence 20 AA;

XX Query Match 92.9%; Score 79; DB 5; Length 20;

XX Best Local Similarity 75.0%; Pred. No. 1e-06; Mismatches 0; Indels 5; Gaps 0;

XX Qy 1 TGYYXXXXQSPEKSLEWIG 20

XX Db 1 TGYYMQWVKQSPEKSLEWIG 20

RESULT 5

ADF70140 ID ADF70140 standard; peptide; 20 AA.

XX AC ADF70140;

XX DT 26-FEB-2004 (First entry)

XX DE Anti-idiotype antibody related peptide.

XX KW autoimmune disease-associated autoantibody; autoantibody;

KW autoimmune disease; immunoglobulin; anti-idiotypic antibody;

KW anti-idiotype antibody related peptide.

XX KW autoimmune disease; immunoglobulin; anti-idiotypic antibody;

KW immunosuppressive; antiinflammatory; dermatological; muscular;
KW neuroprotective; CNS; anti-HIV; nootropic; neuroleptic; antithyroid;
KW thymonimetic; antidiabetic; anabolic; hypertensive; endocrine;
KW antiparotid; hepatotropic; virucide; antiandemic; haemostatic;
KW gastrointestinal; antiulcer; antiinfertility; antirheumatic;
KW antiarthritic; nephrotropic; antiarteriosclerotic; cardiant;
KW ophthalmological; uropathic; antipyretic; vaccine.
XX Synthetic.

OS XX PN WO2003099868-A2.

XX XX DR WPI; 2004-042771/04.

XX XX PD 04-DEC-2003.

XX XX PT Identifying molecules, which mimic an idiotype of an autoimmune disease-associated autoantibody, useful for treating an autoimmune disease, e.g. myasthenia gravis, comprises the use of immunoglobulins purified from pooled plasma.

XX XX PT Example 3; Page 12; 43pp; English.

XX XX The present invention describes a method (M1) for identifying molecules CC (I) which mimic an idiotype of an autoimmune disease-associated CC autoantibody (autoantibodies). M1 comprises purifying autoantibodies from CC sera of one or more patients afflicted with the autoimmune disease,

CC binding the autoantibodies to a solid phase to form an affinity matrix,

CC contacting pooled plasma or B cells comprising immunoglobulins with the

CC affinity matrix followed by removal of unbound plasma components, eluting

CC bound immunoglobulins, being anti-idiotypic antibodies (anti-Id) to

CC autoantibodies, from the matrix, providing a molecular library comprising

CC several molecule members, and contacting the anti-Id with the molecular

CC library and isolating the bound molecules, which are bound by the anti-

CC Id, the bound molecules being molecules that mimic an idiotype of

CC the autoantibodies. (I) have immunosuppressive, antiinflammatory,

CC dermatological, muscular, neuroprotective, CNS, anti-HIV, nootropic,

CC neuroleptic, antithyroid, thyromimetic, antidiabetic, anabolic,

CC hyperactive, endocrine, antisporotic, hepatotropic, virucide,

CC antianæmic, haemostatic, gastrointestinal, antiulcer, antiinflammtory,

CC anti rheumatic, antiarthritic, nephrotropic, antiarteriosclerotic,

CC cardiant, ophthalmological, uropathic and antipyretic activities, and can

CC be used in vaccines. The molecules (I), anti-Id and pharmaceutical

CC compositions of the present invention can be used for treating a patient

CC afflicted with an autoimmune disease. The molecules (I) are also useful

CC for screening chemical compounds for their potential use in treating an

CC autoimmune disease. The present sequence is given in the exemplification

XX SQ Sequence 20 AA;

XX Query Match 92.9%; Score 79; DB 8; Length 20;

XX Best Local Similarity 75.0%; Pred. No. 1e-06; Mismatches 0; Indels 5; Gaps 0;

XX Qy 1 TGYYXXXXQSPEKSLEWIG 20

XX Db 1 TGYYMQWVKQSPEKSLEWIG 20

RESULT 6

ADR14717 ID ADR14717 standard; peptide; 20 AA.

XX AC ADR14717;

XX KW autoimmune disease; immunoglobulin; anti-idiotypic antibody;

XX 21-OCT-2004 (first entry)
 DT XX Synthetic peptide based on VH CDR1 of monoclonal antibody 5G12.
 DE XX complementarity determining region; CDR; heavy chain; light chain;
 KW XX monoclonal anti-DNA 16/6 idiotype antibody; 16/6 Id antibody;
 KW anti-DNA antibody; induces systemic lupus erythematosus; SLE;
 KW antibody 5G12.
 OS XX Synthetic.
 PN WO2004064787-A2.
 PD XX 05-AUG-2004.
 PF XX 14-JAN-2004; 2004WO-US000948.
 PR XX 14-JAN-2003; 2003US-0439918P.
 PA (TEVA-) TEVA PHARM IND LTD.
 PA (TEVA-) TEVA PHARM USA INC.
 PI XX Cohen-Vered S, Naftali B, Weinstein V, Gilbert A, Klinger E;
 DR XX WPI; 2004-580636/56.
 PT XX pharmaceutical composition for treating systemic lupus erythematosus
 PT (SLE), has salt of peptide corresponding to complementarity-determining
 PT region of heavy/light chain of anti-DNA 16/6 Id antibody that induces
 PT immune response to SLE.
 PS XX Claim 3; SEQ ID NO 1; 132pp; English.
 XX The specification describes a pharmaceutical composition, comprising a
 CC salt of a peptide with 12-30 consecutive amino acids having a sequence
 CC corresponding to an amino acid sequence found within complementarity-
 CC determining region (CDR) of the heavy or light chain of the human
 CC monoclonal anti-DNA 16/6 idiotype (16/6 Id) antibody, or a heavy or light
 CC chain of a pathogenic anti-DNA monoclonal antibody that induces systemic
 CC lupus erythematosus (SLE)-like disease response in mice. The composition
 CC is useful for treating SLE and for alleviating symptoms of SLE in a human
 CC subject. The present sequence represents a peptide based on CDR1 of the
 CC heavy chain V region of monoclonal antibody 5G12. The 5G12 monoclonal
 CC antibody was isolated from mice with experimental SLE, and was shown to
 CC bind DNA and bear the 16/6 Id. The present peptide is used in
 CC pharmaceutical compositions of the invention.
 SQ XX Sequence 20 AA:
 Query Match 1 TGYYXXXXQSPEKSLEWIG 20
 Best Local Similarity 92.9%; Pred. No. 1e-06;
 Matches 15; Conservative 0;- Mismatches 5; Indels 0;
 Gaps 0;
 OS XX Mus musculus.
 PN WO2006006693-A1.
 XX 19-JAN-2006.
 PR XX 08-JUL-2005; 2005WO-JP013103.
 PA (CHUS) CHUGAI SEIYAKU KK.
 XX
 RESULT 7
 ADM72027 standard; protein; 470 AA.
 AC XX ADM72027;
 DT XX 03-JUN-2004 (first entry)
 DE XX Chimeric mouse-human antibody M1E07 heavy chain.
 KW XX GPC3; Glycan 3; anti-GPC3 antibody; cell disruption; anti-cancer;
 KW cytosstatic; M1E07.
 OS XX Mus sp.

OS Homo sapiens.
 OS Chimeric.
 XX WO2004022739-A1.
 XX 18-MAR-2004.
 PD XX 04-SEP-2003; 2003WO-JP011318.
 PR XX 04-SEP-2002; 2002WO-JP008999.
 PA (CHUS) CHUGAI SEIYAKU KK.
 XX Aburutani H, Midorikawa Y, Nakano K, Ohizumi I, Ito Y, Tokita S;
 PI XX DR WPI; 2004-269573/25.
 DR XX N-PSbs; ADM72026.
 XX PT Antibody against the N terminus of glycan 3(GPC3) causes cell
 PT disruption and is useful as an anticancer agent.
 XX PS Example 4; SEQ ID NO 12; 122pp; Japanese.
 XX The invention relates to an antibody against the N terminus of glycan 3
 CC (GPC3). The antibody can be used for causing cell disruption and can be
 CC used as an anti-cancer agent. The present sequence represents a chimeric
 CC mouse-human antibody M1E07 heavy chain.
 XX SQ Sequence 470 AA;
 Query Match 1 TGYYXXXXQSPEKSLEWIG 20
 Best Local Similarity 92.9%; Pred. No. 3.3e-05;
 Matches 15; Conservative 0;- Mismatches 5; Indels 0;
 Gaps 0;
 DE XX
 RESULT 8
 AEF50993 standard; protein; 470 AA.
 ID XX AEF50993;
 AC XX AEF50993;
 DT XX 23-MAR-2006 (first entry)
 DE XX Variable region of anti-glycan-3 antibody, SEQ ID NO:24.
 DE XX humanized antibody; antibody engineering; cell growth; cancer;
 DE XX cytostatic; neoplasm; hepatocellular carcinoma; gastrointestinal disease;
 DE XX diagnosis; glycan-3; GPC3.
 DE XX Mus musculus.
 PN XX WO2006006693-A1.
 PR XX 19-JAN-2006.
 PA (CHUS) CHUGAI SEIYAKU KK.
 XX
 RESULT 7
 ADM72027 standard; protein; 470 AA.
 AC XX ADM72027;
 DT XX 03-JUN-2004 (first entry)
 DE XX Chimeric mouse-human antibody M1E07 heavy chain.
 KW XX GPC3; Glycan 3; anti-GPC3 antibody; cell disruption; anti-cancer;
 KW cytosstatic; M1E07.
 OS XX Novel anti-glycan 3 antibody having high complement dependent and
 PT antibody dependent cell-mediated cytotoxicity activity with respect to
 PT cell expressing glycan 3, useful as anticancer agent and as cell growth

PT inhibitor.
 XX Disclosure; SEQ ID NO 24; 184pp; Japanese.
 XX The new invention relates to an anti-glycan 3 (GPC3) antibody (A1) comprising a heavy chain variable region having CDR1, CDR2 and CDR3 and a light chain variable region having CDR1, CDR2 and CDR3. The antibody (A1) comprises complementarity determining regions (CDRs) of amino acid sequence selected from a number of sequences fully defined in the specification. The antibody may be humanized. Also described is an antibody (A2) having an activity equivalent to (A1) and having a sequence comprising one or several amino acid substitutions to (A1), deletions, additions and/or insertions in the sequence of (A1); poly(mucleotide) (N1) encoding the heavy-chain variable region or light-chain variable region of (A1); cell growth inhibitor (I) comprising (A1) as an active ingredient; and peptide (P1) having an amino acid sequence comprising amino acid residues 524-533, 537-563, 544-553 or 546-551 of glycan 3. (I) is useful as a cell growth inhibitor. (II) is useful as an anticancer, preferably useful for treating hepatoma. (I) is useful as an anticancer agent and as a cell growth inhibitor. (I) is useful for diagnosing cancer. (A1) has CDC and ADCC activity. The present sequence is a variable region of a murine anti -glycan-3 antibody.
 XX Sequence 470 AA;

Query Match 92.9%; Score 79; DB 10; Length 470;
 Best Local Similarity 75.0%; Pred. No. 3.3e-05; Gaps 0;
 Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 Qy 1 TGYYYYXXOSPEKSLEWIG 20
 ||||| | | | | | | | | | | |
 Db 49 TGYYMWKVKQSKPEKSLEWIG 68

RESULT 9
 ABP45615 standard; protein; 255 AA.
 XX AC ABP45615;
 XX DT 19-AUG-2002 (first entry)
 XX DE Human Blys binding scFv SEQ ID 1626.
 XX Blys; B lymphocyte stimulator; TNF superfamily; human; cytostatic; tumour necrosis factor; B cell proliferation; B cell differentiation; immunosuppressive; immunostimulant; immunomodulatory; antirheumatic; antiAIDS; vaccine; cancer; immune; autoimmune disorder; immunodeficiency; systemic lupus erythematosus; rheumatoid arthritis; AIDS; common variable immunodeficiency; acquired immunodeficiency syndrome.
 XX OS Homo sapiens.
 XX PN WO200202641-A1.
 XX PD 10-JAN-2002.
 XX PF 15-JUN-2001; 2001WO-US019110.
 XX PR 16-JUN-2000; 2000US-0212210P.
 PR 17-OCT-2000; 2000US-0240816P.
 PR 16-MAR-2001; 2001US-0276348P.
 PR 21-MAR-2001; 2001US-0277379P.
 PR 25-MAY-2001; 2001US-0293499P.
 XX PA (HUMA-) HUMAN GENOME SCI INC.
 XX (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.

XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 XX DR WPI; 2002-114799/15.
 XX PS WO200202641-A2.
 XX PD 10-JUL-2003.
 XX PR 14-NOV-2002; 2002WO-US036495.
 XX PF 16-NOV-2001; 2001US-0331469P.
 PR 19-DEC-2001; 2001US-0340817P.
 XX PA (HUMA-) HUMAN GENOME SCI INC.
 XX PI Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
 XX DR WPI; 2003-505530/47.
 XX PA Novel antibody that immunospecifically binds to a B lymphocyte stimulator (Blys), useful for detecting and treating diseases or disorders e.g. rheumatoid arthritis, asthma and leukemia.
 XX PS Example 1; SEQ ID NO 1626; 394pp; English.
 XX

PT Antibodies against B Lymphocyte Stimulating polypeptides, useful for the diagnosis and treatment of cancers and immune disorders.
 XX Claim 1; Page 2343-2344; 3148pp; English.
 CC This invention describes novel antibodies that immunospecifically bind to B Lymphocyte Stimulator (Blys) polypeptides. Blys is a member of the tumour necrosis factor (TNF) super family and induces B cell proliferation and differentiation. The antibodies of the invention have cyrostatic, immunosuppressive, immunostimulant, immunomodulatory, antineumatic and antiAIDS activity and can be used in vaccines to inhibit the expression and activity of Blys. The antibodies bind to Blys and so may be used to detect and quantitate the presence of Blys in biological samples and may be used in this way to diagnose disease associated with aberrant expression of Blys. They may also be administered to treat diseases associated with aberrant Blys expression such as cancer, immune, and autoimmune disorders and diseases, e.g. systemic lupus erythematosus, rheumatoid arthritis, immunodeficiency (e.g. common variable immunodeficiency (CVID) and acquired immunodeficiency syndrome (AIDS)). ABP45615 is ABP45615 represent the antibodies and fragments of the antibodies described in the method of the invention.
 CC SQ Sequence 255 AA;
 CC Query Match 83.5%; Score 71; DB 5; Length 255;
 CC Best Local Similarity 65.0%; Pred. No. 0.00045;
 CC Matches 13; Conservative 1; Mismatches 6; Indels 0; Gaps 0;
 CC Qy 1 TGYYYYXXOSPEKSLEWIG 20
 CC :||||| | | | | | | | | | |
 CC Db 30 SGYIWSWTRQSPERGLEWIG 49
 CC
 RESULT 10
 ADC96442
 ID ADC96442 standard; protein; 255 AA.
 XX AC ADC96442;
 XX DT 11-MAR-2004 (first entry)
 XX DE Single chain antibody that immunospecifically binds Blys SEQID 1626.
 XX KW antibody; B lymphocyte stimulator; Blys; tumour necrosis factor; B cell proliferation; differentiation; scFv; myasthenia gravis; multiple sclerosis; asthma; rheumatoid arthritis; AIDS; leukaemia; carcinoma; lymphoma; antirheumatic; antiarthritic; neuroprotective; antiinflammatory; antiasthmatic; cytostatic.
 XX OS Unidentified.
 XX PN WO2003055979-A2.
 XX PD 10-JUL-2003.
 XX PR 14-NOV-2002; 2002WO-US036495.
 XX PF 16-NOV-2001; 2001US-0331469P.
 PR 19-DEC-2001; 2001US-0340817P.
 XX PA (HUMA-) HUMAN GENOME SCI INC.
 XX PI Ruben SM, Barash SC, Choi GH, Vaughan TJ, Hilbert D;
 XX DR WPI; 2003-505530/47.
 XX PA Novel antibody that immunospecifically binds to a B lymphocyte stimulator (Blys), useful for detecting and treating diseases or disorders e.g. rheumatoid arthritis, asthma and leukemia.
 XX PS Example 1; SEQ ID NO 1626; 394pp; English.
 XX

This invention relates to novel antibodies that immunospecifically bind to B lymphocyte stimulator (Blys). The Blys gene has been mapped to chromosome 13q34 and encodes a protein that is a member of the tumor necrosis factor superfamily and induces both in vivo and in vitro B cell proliferation and differentiation. Specifically, it refers to single chain antibody molecules (scFvs) derived, preferably, from the variable heavy CDR3 region that immunospecifically bind to a polypeptide, or fragment thereof, of either human, murine, rat or monkey Blys. The present invention refers to the use of such antibodies in various methods for the detection, diagnosis and prognosis of diseases related to the aberrant expression or inappropriate function of Blys or its receptor. As such, these compositions are useful for identifying immune disorders including myasthenia gravis and multiple sclerosis, inflammatory disorders e.g. asthma and rheumatoid arthritis, infectious diseases such as AIDS and proliferative disorders including leukaemia, carcinoma and lymphoma. Accordingly, they can be described as exhibiting various activities such as antiinflammatory, antiarthritic, neuroprotective, antiinflammatory, antiarthritic, antiallergic and cytostatic. This polypeptide sequence is a single chain antibody that binds Blys of the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp://wipo.int/pub/published/pct_sequences.

Sequence 255 AA;

Query Match	83.5%;	Score 71;	DB 7;	Length 255;
Best Local Similarity	65.0%;	Pred. No.	0.00045;	
Matches	13;	Conservative	1;	Mismatches 6;
Indels	0;	Gaps	0;	

Qy 1 TGYXXXXXQSPEKSLEWIG 20
 Db 30 SGYXMSWRQSPEKGLEWIG 49

RESULT 11
 AED78495
 ID AED78495 standard; protein; 255 AA.
 XX AC AED78495;
 XX DT 12-JAN-2006 (first entry)

XX DE Human B Lymphocyte binding scFv fragment protein, SEQ ID 1626.
 KW Antiinflammatory; Dermatological; Immunosuppressive; Antirheumatic;
 KW Antiarthritic; Neuroprotective; Muscular-Gen.; Antiasmstatic;
 KW Antiallergic; Antimicrobial; Anti-HIV; Cytostatic; B-lymphocyte;
 KW antibody; autoimmune disease; b-cell lymphoma;
 KW systemic lupus erythematosus; rheumatoid arthritis; immune disorder;
 KW inflammation; infectious disease; hyperproliferation.
 XX OS Homo sapiens.
 XX PN US200525532-A1.
 XX PD 17-NOV-2005.
 XX PF 10-FEB-2005; 2005US-00054515.

PR 16-JUN-2000; 2000US-0212210P.
 PR 17-OCT-2000; 2000US-0240816P.
 PR 16-MAR-2001; 2001US-0276238P.
 PR 21-MAR-2001; 2001US-0277379P.
 PR 25-MAY-2001; 2001US-0293399P.
 PR 16-NOV-2001; 2001US-03880748.
 PR 19-DEC-2001; 2001US-0331469P.
 PR 14-NOV-2002; 2002US-00293418.
 PR 11-FEB-2004; 2004US-0543296P.
 PR 18-JUN-2004; 2004US-0580347P.
 XX PA (RUBE/) RUBEN S M.
 PA (BARA/) BARASH S C.

PA (CHOI/) CHOI G H.
 PA (VAUGHN) VAUGHN T.
 PA (HILBERT) HILBERT D.
 XX PI Ruben SM, Barash SC, Choi GH, Vaughan T, Hilbert D;
 XX DR WPI; 2005-808635/82.
 XX PT New antibodies that immunospecifically binds to B Lymphocyte stimulator protein, useful for diagnosing, treating, or preventing autoimmune disease, e.g. systemic lupus erythematosus or rheumatoid arthritis, or B cell cancer.
 XX PS Claim 1; SEQ ID NO 1626; 240pp; English.
 XX The invention relates to a novel antibody that immunospecifically binds to a B Lymphocyte Stimulator protein. The protein comprises an amino acid sequence that is 85% identical to the VH domain of any one of the single-chain variable fragments (scFvs) of SEQ ID NOS. 1-2128, and/or an amino acid sequence that is at least 85% identical to the VL domain of any one of the scFvs of SEQ ID NOS. 1-2128. The invention further comprises: an isolated nucleic acid molecule encoding the antibody; an isolated cell line that expresses the antibody; a method for detecting the expression of a B Lymphocyte Stimulator protein; a method for diagnosing an autoimmune disease or a B cell cancer; and a method for treating, preventing, or ameliorating an autoimmune disease or a B cell cancer. The invention relates to a novel antibody that immunospecifically binds to a B Lymphocyte Stimulator protein, and in diagnosing, treating, preventing, or ameliorating an autoimmune disease or a B cell cancer. The autoimmune disease is systemic lupus erythematosus or rheumatoid arthritis. It can also be used for diagnosing, treating, and preventing immune disorders (e.g. multiple sclerosis, myasthenia Gravis, or Hashimoto's disease), inflammatory disorders (e.g. asthma or allergic disorders), infectious diseases (e.g. AIDS), and proliferative disorders (e.g. leukemia, carcinoma, or lymphoma). This sequence represents a single-chain variable fragment polypeptide that immunospecifically binds to a B Lymphocyte Stimulator protein of the invention. Note: This sequence is not shown in the specification. It has been electronically downloaded from the USPTO website.
 XX SQ Sequence 255 AA;
 XX Query Match 83.5%; Score 71; DB 9; Length 255;
 XX Best Local Similarity 65.0%; Pred. No. 0.00045;
 XX Matches 13; Conservative 1; Mismatches 6; Indels 0; Gaps 0;
 XX Qy 1 TGYYXXXXQSPEKSLEWIG 20
 XX Db 30 SGYXMSWRQSPEKGLEWIG 49
 RESULT 12
 ADZ51037
 DT 30-JUN-2005 (first entry)
 XX ID ADZ51037 standard; protein; 467 AA.
 XX AC ADZ51037;
 XX DT 30-JUN-2005
 XX DE Amino acid sequence of heavy chain of anti-H4-1BB antibody.
 XX KW antibody therapy; H4-1BB; CD137; IgG4; cytostatic; immunosuppressive;
 KW antiinflammatory; antimicrobial; gene therapy;
 KW T cell mediated autoimmune disease; cancer; neoplasm; autoimmune disease;
 KW inflammatory disease; infectious disease; heavy chain.
 XX OS Synthetic.
 XX PH Key
 FT Peptide 1..19
 /note= "leader peptide"
 XX PN WO2005035584-A1.

XX PR 10-OCT-2003; 2003US-0510193P.
 XX PR 08-OCT-2004; 2004US-00961567.
 XX PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 PR XX
 Jure-Kunkel M, Hefta LJ, Santoro M, Ganguly S;
 XX PI
 DR WPI; 2005-296269/30.
 DR N-PSDB; ADZ51041.
 XX PT New monoclonal antibody that specifically binds to 4-1BB comprises a light chain variable region and a heavy chain variable region, useful for treating cancer, autoimmune diseases, inflammatory diseases, or infectious diseases.
 XX Example 1; SEQ ID NO 9; 92pp; English.
 PS The specification describes fully human antibodies against human 4-1BB (CD137) (H4-1BB). These antibodies are especially IgG4 antibodies.
 XX CC Antibodies for human 4-1BB are useful as immuno-enhancers of an anti-tumor or anti-viral immune response, or as immunomodulators of T cell mediated autoimmune disease. They can also be used as diagnostic tools for the detection of H4-1BB in blood or tissues of patients with cancer, autoimmune, or other disease. The antibody can also be used for treating cancer (prostate cancer, melanoma, or epithelial cancer), autoimmune diseases (multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, or myasthenia gravis), inflammatory diseases, and infectious diseases. ADZ51041, ADZ51042, and ADZ51043 represent the coding strand, complementary strand, and encoded protein of a construct encoding the heavy chain of an antibody of the invention.
 XX SQ Sequence 470 AA;
 Query Match 83.5%; Score 71; DB 9; Length 470;
 Best Local Similarity 65.0%; Pred. No. 0.00088;
 Matches 13; Conservative 1; Mismatches 6; Indels 0; Gaps 0;
 Oy 1 TGYYXXXXXOSPBKSLIEWIG 20
 Db 49 SGTYWSWIRQSPERGLEWIG 68
 RESULT 14
 ADD28121 standard; protein; 97 AA.
 XX ID ADD28121;
 XX AC ADD28121;
 XX DT 15-JAN-2004 (first entry)
 XX DE Lymphoma related immunoglobulin variable region.
 XX KW B-cell; malignant; immunoglobulin; immunoglobulin variable region;
 XX KW Ig variable region; glycosylation site; lymphoma; B cell receptor;
 DB KW cytosatic; gene therapy; glycosylation inhibitor;
 KW KW non-Hodgkin's lymphoma.
 OS KW Synthetic.
 XX OS Homo sapiens.
 PN WO2003074059-A2.
 XX PD 12-SEP-2003.
 XX Key Location/Qualifiers
 FT 1_19
 Peptide /note= "leader peptide"
 XX PN WO200305584-A1.
 XX PD 21-APR-2005.
 XX PR 12-OCT-2004; 2004WO-US033587.
 XX PR 21-APR-2005.
 XX PR 12-OCT-2004; 2004WO-US033587.
 XX PR 10-OCT-2003; 2003US-0510193P.
 XX PR 08-OCT-2004; 2004US-00961567.
 XX PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 PR XX
 Jure-Kunkel M, Hefta LJ, Santoro M, Ganguly S;
 XX PI
 DR WPI; 2005-296269/30.
 DR N-PSDB; ADZ51041.
 XX PT New monoclonal antibody that specifically binds to 4-1BB comprises a light chain variable region and a heavy chain variable region, useful for treating cancer, autoimmune diseases, inflammatory diseases, or infectious diseases.
 XX Example 1; SEQ ID NO 9; 92pp; English.
 PS The specification describes fully human antibodies against human 4-1BB (CD137) (H4-1BB). These antibodies are especially IgG4 antibodies.
 XX CC Antibodies for human 4-1BB are useful as immuno-enhancers of an anti-tumor or anti-viral immune response, or as immunomodulators of T cell mediated autoimmune disease. They can also be used as diagnostic tools for the detection of H4-1BB in blood or tissues of patients with cancer, autoimmune, or other disease. The antibody can also be used for treating cancer (prostate cancer, melanoma, or epithelial cancer), autoimmune diseases (multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, or myasthenia gravis), inflammatory diseases, and infectious diseases. ADZ51035, ADZ51036, and ADZ51037 represent the coding strand, complementary strand, and encoded protein of a plasmid. This plasmid encodes the heavy chain of an antibody of the invention.
 XX SQ Sequence 467 AA;
 Query Match 83.5%; Score 71; DB 9; Length 467;
 Best Local Similarity 65.0%; Pred. No. 0.00087;
 Matches 13; Conservative 1; Mismatches 6; Indels 0; Gaps 0;
 Oy 1 TGYYXXXXXOSPBKSLIEWIG 20
 Db 49 SGTYWSWIRQSPERGLEWIG 68
 RESULT 13
 ADZ51043
 ID ADZ51043 standard; protein; 470 AA.
 XX AC ADZ51043;
 XX DT 30-JUN-2005 (first entry)
 DB Amino acid sequence of heavy chain of anti-H4-1BB antibody.
 XX antibody therapy; H4-1BB; CD137; IgG4; cytostatic; immunosuppressive;
 XX antiinflammatory; antimicrobial; gene therapy;
 KW T cell mediated autoimmune disease; cancer; neoplasm; autoimmune disease;
 KW inflammatory disease; infectious disease; heavy chain.
 XX OS Synthetic.
 XX FH Location/Qualifiers
 FT 1_19
 Peptide /note= "leader peptide"
 XX PN WO200305584-A1.
 XX PD 21-APR-2005.
 XX PR 12-OCT-2004; 2004WO-US033587.

DR WPI; 2003-902720/82.
 PT Classifying a B-cell as malignant or normal by isolating a sequence representing an Ig variable region from the B cell, detecting the presence of a glycosylation site and classifying the cell as malignant or normal.
 XX Disclosure; Fig 4; 61pp; English.
 XX The present invention describes a method for classifying a B-cell as malignant or normal comprising: (a) isolating a sequence representing an immunoglobulin (Ig) variable region from the B cell; (b) detecting the presence of glycosylation site; and (c) classifying the cell as malignant or normal on the basis of the presence or absence of a glycosylation site. Also described: (1) treating a patient suffering from or at risk of having lymphoma; (2) screening for substances capable of inhibiting glycosylation of the Ig variable region of the B cell receptor; and (3) screening for substances (S) capable of inhibiting the interaction between lectins of the type found in the germinal centre and N-glycans found on the surface of Ig of lymphoma cells. (S) has cytostatic activity, and can be used in gene therapy, and as a glycosylation inhibitor. The method is useful in classifying a B-cell as malignant or normal. The Glycosylation inhibitor is useful in preparing a medicament for treating non-Rodgkin's lymphoma. The present sequence represents an Ig variable region sequence which is used in the exemplification of the present invention.

XX Sequence 97 AA:
 Query Match 82.4%; Score 70; DB 7; Length 97;
 Best Local Similarity 68.4%; Pred. No. 0.00024;
 Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 AC ABP58454;
 DT 14-APR-2003 (first entry)
 DE Engineered superantigen for human cancer therapy.
 KW Superantigen; staphylococcal enterotoxin; antibody; cancer; tumour;
 KW cytostatic; vaccine; human; SEA/E-120; mutant; mutein.
 XX Homo sapiens.
 OS Staphylococcus sp.
 OS Synthetic.
 OS Chimeric.
 XX

RESULT 15
 ABP58454 standard; protein; 672 AA.

XX ABP58454 standard; protein; 672 AA.

AC ABP58454;

DT 14-APR-2003 (first entry)

DE Engineered superantigen for human cancer therapy.

KW Superantigen; staphylococcal enterotoxin; antibody; cancer; tumour;

KW cytostatic; vaccine; human; SEA/E-120; mutant; mutein.

XX Homo sapiens.

OS Staphylococcus sp.

OS Synthetic.

OS Chimeric.

XX

FH Key

FT Region 1. .120

FT Misc-difference 41 "note= "5T4 variable heavy chain"

FT Misc-difference 44 "note= "wild-type His substituted by Pro"

FT Misc-difference 69 "note= "wild-type Ser substituted by Gly"

FT Misc-difference 113 "note= "wild-type Ile substituted by Thr"

FT Region 121. .222 "note= "wild-type Val substituted by Gly"

FT Region 226. .458 "note= "C242 constant heavy chain"

FT Misc-difference 245 "note= "SEA/E-120"

FT Misc-difference 246 "note= "wild-type Arg substituted by Gly"

PT Misc-difference 246 /note= "wild-type Asn substituted by Thr"
 FT Misc-difference 249 /note= "wild-type Ser substituted by Gly"
 PT Misc-difference 252 /note= "wild-type Arg substituted by Lys"
 PT Misc-difference 304 /note= "wild-type Lys substituted by Glu"
 XX
 PT Misc-difference 306 /note= "wild-type Lys substituted by Glu"
 FT Misc-difference 308 /note= "wild-type Lys substituted by Ser"
 PT Misc-difference 309 /note= "wild-type Lys substituted by Ser"
 PT Misc-difference 452 /note= "wild-type Lys substituted by Ser"
 PT Region 459. .565 "note= "5T4 variable light chain"
 PT Misc-difference 469 /note= "wild-type Asp substituted by Ser"
 PT Misc-difference 504 /note= "wild-type Phe substituted by Ser"
 PT Misc-difference 504 /note= "wild-type Thr substituted by Lys"
 PT Misc-difference 522 /note= "wild-type Ile substituted by Ser"
 PT Misc-difference 532 /note= "wild-type Phe substituted by Leu"
 PT Misc-difference 536 /note= "wild-type Thr substituted by Ser"
 PT Misc-difference 537 /note= "wild-type Thr substituted by Ser"
 PT Misc-difference 542 /note= "wild-type Ile substituted by Ala"
 PT Region 566. .672 "note= "C242 constant light chain"
 XX WO2003002143-A1.
 XX PD 09-JAN-2003.
 XX PP 19-JUN-2002; 2002WO-SE001188.
 XX PR 28-JUN-2001; 2001SE-0002327.
 XX PA (ACTI-) ACTIVE BIOTECH AB.
 XX PI Forsberg G, Erlandsson E, Antonsson P, Walse B;
 XX DR WPI; 2003-201467/19.
 XX Conjugate for therapy, has bacterial superantigen with a region in T-cell receptor and four regions to determine binding to class II major histocompatibility complex, antibody to cancer associated cell surface structure.
 XX Claim 12; Fig 10; 102pp; English.
 XX
 CC The present sequence is a conjugate of a bacterial superantigen and an antibody moiety, and has been designed to target and destroy cancer cells. The bacterial superantigen is SEA/E-120 (see also ABP58455), which was derived from staphylococcal enterotoxin E (SEE) by the incorporation of the following amino acid substitutions to reduce seroreactivity whilst maintaining production levels and biological activity: R40G, N21T, S24G, R27K, K79E, K81E, K83S and D22T/S. SEA/E-120 was genetically fused to the Fab moiety of the tumour reactive antibody 5T4. Substitutions were made in the 5T4 sequence to obtain higher yields in the heavy chain, H41P, C44G, I69T and V113G; and in the light chain, F10S, T45K, I63S, F73L, T77S, L78V and L83A. An expression vector comprising DNA encoding the conjugate can be used to transform host cells for recombinant production of the conjugate. The conjugate is useful for treating cancer, including cancer of the lung, breast, colon, kidney, pancreas, ovary, stomach, cervix and prostate (claimed)
 XX Sequence 672 AA.
 SQ

Query Match 80.0%; Score 68; DB 6; Length 672;
Best Local Similarity 65.0%; Pred. No. 0.0044; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
Qy 1 TGYYXXXXQSPEKSLEWIG 20
Db 30 TGYYMMHWKQSPGKGLEWIG 49

Search completed: October 18, 2006, 19:26:43
Job time : 95.299 secs

Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: October 18, 2006, 19:27:25 ; Search time 13.299 Seconds
(without alignments)

144.698 Million cell updates/sec

Title: US-10-620-621-1

Perfect score: 85

Sequence: 1 TGYYXXXXQSPEKSLIEWIG 20

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing First 45 summaries

Database : PIR 80:*

- 1: pir1:*
- 2: pir2:*
- 3: pir3:*
- 4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	79	92.9	105	2 PH0978	Ig heavy chain V r
2	63	74.1	107	2 S26320	Ig heavy chain V r
3	63	74.1	108	2 PH0977	Ig heavy chain V r
4	63	74.1	120	2 A49982	Ig heavy chain V r
5	62	72.9	129	1 D2HIIWA	Ig heavy chain V-I
6	61	71.8	115	2 S57464	Ig heavy chain V-J
7	60	70.6	136	2 A31933	Ig heavy chain pre
8	59	69.4	91	2 S13689	Ig heavy chain V r
9	59	69.4	97	2 S26898	Ig heavy chain V r
10	59	69.4	97	2 S26806	Ig heavy chain V r
11	59	69.4	97	2 S26805	Ig heavy chain V r
12	59	69.4	97	2 S14474	Ig heavy chain V r
13	59	69.4	98	2 S14704	Ig heavy chain V r
14	59	69.4	106	2 S37454	Ig mu chain - huma
15	59	69.4	110	2 S13688	Ig heavy chain V4.
16	59	69.4	111	2 S13687	Ig heavy chain pre
17	59	69.4	112	2 S13686	Ig heavy chain V r
18	59	69.4	112	2 S13685	Ig heavy chain V r
19	59	69.4	114	2 S26119	Ig heavy chain V-I
20	59	69.4	122	2 JL0047	Ig heavy chain V r
21	59	69.4	126	2 S47010	Ig heavy chain V4.
22	59	69.4	135	2 PS0057	Ig heavy chain pre
23	59	69.4	140	2 S78052	Ig heavy chain V r
24	59	69.4	140	2 A49045	Ig heavy chain V r
25	58	68.2	96	2 P34964	Ig heavy chain V-I
26	58	68.2	98	2 S26112	Ig heavy chain V r
27	58	68.2	98	2 S26338	Ig heavy chain V r
28	58	68.2	98	2 S26902	Ig heavy chain V r
29	58	68.2	98	2 S12421	Ig heavy chain V r

ALIGNMENTS

RESULT 1						
PH0978	Ig heavy chain V region (clone 17s.166) - mouse (fragment)					
C:Species: Mus musculus (house mouse)						
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 21-Jan-2000						
C:Accession: PH0978						
R:Tillmann, D.M.; Jou, N.T.; Hill, R.J.; Marion, T.N.						
J. Exp. Med. 176, 761-779, 1992						
A:Title: Both IgM and IgG anti-DNA antibodies are the products of cionally selective B						
A:Reference number: PH0971; MUID:1512540						
A:Accession: PH0978						
A:Status: nucleic acid sequence not shown						
A:Molecule type: mRNA						
A:Cross references: 1-105 <TIL>						
A:Residues: TGYTXXXXXXXXXQSPEKSLIEWIG 20						
A:Experimental source: B cell, strain [NZB x NZW]F1						
C:Superfamily: immunoglobulin V region; immunoglobulin homology						
C:Keywords: heterotetramer; immunoglobulin P;14-97/Domain: immunoglobulin homology <IMM>						
Query Match	Score 99:	Score 79:	DB 2:	Length 105:	Best Local Similarity 75.0%:	Pred. No. 7.7e-07;
Qy	1 TGYTXXXXXXXXXQSPEKSLIEWIG 20				Mismatches 0;	Indels 0;
Db	29 TGYTMHHWVHQSQPEKSLIEWIG 48				Gaps 0;	

RESULT 2						
S26320	Ig heavy chain V region - mouse					
C:Species: Mus musculus (house mouse)						
C:Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 21-Jan-2000						
C:Accession: S26320						
R:Stark, S.E.; Caton, A.J.						
J. Exp. Med. 174, 613-624, 1991						
A:Title: Antibodies that are specific for a single amino acid interchange in a protein						
A:Reference number: S26309; MUID:1908510						
A:Accession: S26320						
A:Status: preliminary						
A:Molecule type: mRNA						
A:Cross references: 1-107 <STA>						
A:Residues: TGYTXXXXXXXXXQSPEKSLIEWIG 20						
A:Experimental source: B cell, strain [NZB x NZW]F1						
C:Superfamily: immunoglobulin V region; immunoglobulin homology						
C:Keywords: heterotetramer; immunoglobulin P;14-97/Domain: immunoglobulin homology <IMM>						
F:3-86/Domain: immunoglobulin homology <IMM>						
Query Match	Score 63:	Score 63:	DB 2:	Length 107:	Best Local Similarity 65.0%:	Pred. No. 0.00056;
Qy	1 TGYTXXXXXXXXXQSPEKSLIEWIG 20				Mismatches 7;	Indels 0;
Db	29 TGYTMHHWVHQSQPEKSLIEWIG 48				Gaps 0;	

Qy 1 TGYYXXXXQSPEKSLEWIG 20
 Db 18 TGYYVHNVQSHVKSLEWIG 37

RESULT 3
 PH0977
 Ig heavy chain V region (clone 10-c1) - mouse (fragment)
 C;Species: Mus musculus (house mouse)
 C;Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 21-Jan-2000
 C;Accession: PH0977
 R;Tillman, D. M.; Jou, N. T.; Hill, R. J.; Marion, T. N.
 J. Exp. Med. 176, 761-779, 1992
 A;Title: Both IgM and IgG anti-DNA antibodies are the products of clonally selective B cells
 A;Reference number: PH0971; MUID:92381444; PMID:1512544;
 A;Accession: PH0977
 A;Status: nucleic acid sequence not shown
 A;Molecule type: mRNA
 A;Residues: 1-108 <TLL>
 A;Cross-references: UNIPARC:UPI000176AC9

A;Experimental source: B cell, strain [NZB x NZW]F1
 C;Superfamily: immunoglobulin V region; immunoglobulin homology
 C;Keywords: heterotetramer; immunoglobulin
 F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 74.1%; Score 63; DB 2; Length 108;
 Best Local Similarity 65.0%; Pred. No. 0.00056; Gaps 0;
 Matches 13; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPEKSLEWIG 20
 Db 30 TGYYVHNVQSHVKSLEWIG 49

RESULT 4
 A49982
 Ig heavy chain V region (BA7.1) - mouse (fragment)
 C;Species: Mus musculus (house mouse)
 C;Date: 10-Nov-1995 #sequence_revision 10-Nov-1995 #text_change 21-Jan-2000
 C;Accession: A49982
 R;Lin, C.; Kieber-Emmons, T.; Villalobos, A. P.; Foster, M. H.; Wahlgren, C.; Kleyman, T. R.
 J. Biol. Chem. 269, 2805-2813, 1994
 A;Title: Topology of an amiloride-binding protein.
 A;Reference number: A49982; MUID:94132051; PMID:8300613
 A;Accession: A49982
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-120 <L1N>
 A;Cross-references: UNIPARC:UPI00114AA4; GB:L24802; PIDN:9452096; PIDN:AAA98740.1; PID: A31933

C;Superfamily: immunoglobulin V region; immunoglobulin homology
 C;Keywords: heterotetramer; immunoglobulin
 F;15-98/Domain: immunoglobulin homology <IMM>

Query Match 74.1%; Score 63; DB 2; Length 120;
 Best Local Similarity 65.0%; Pred. No. 0.00063; Gaps 0;
 Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPEKSLEWIG 20
 Db 30 TGYYVHNVQSHVKSLEWIG 49

RESULT 5
 D2HWA
 Ig heavy chain V-II region (wah) - human
 C;Species: Homo sapiens (main)
 C;Date: 05-Apr-1983 #sequence_revision 05-Apr-1983 #text_change 09-Jul-2004
 C;Accession: A02099
 R;Itakoshi, N.; Tetaert, D.; Debuire, B.; Lin, L. C.; Putnam, F. W.
 Proc. Natl. Acad. Sci. U.S.A. 79, 2850-2854, 1982
 A;Title: Complete amino acid sequence of the delta heavy chain of human immunoglobulin D
 A;Reference number: A02099; MUID:8222235; PMID:6806881
 A;Accession: A02099

Query Match 70.6%; Score 60; DB 2; Length 136;
 Best Local Similarity 55.0%; Pred. No. 0.0025; Gaps 0;
 Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPEKSLEWIG 20

Db 47 tsyyvwirqpprktlewig 66

RESULT 8
S13689
Ig heavy chain V region - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 18-Feb-1994 #sequence_revision 10-Nov-1995 #text_change 09-May-1997
C;Accession: S13689
R;Pennell, C.A.; Mercallino, T.J.; Grdina, T.A.; Arnold, L.W.; Haughton, G.; Clarke, S.H.
Bur. J. Immunol. 19, 1289-1295, 1989
A;Title: Biased immunoglobulin variable region gene expression by Ly-1 B cells due to cl
A;Reference number: S13685; MUID:89338557; PMID:2503389
A;Accession: S13689
A;Molecule type: mRNA
A;Residues: 1-91 <PEN>
A;Cross-references: UNIPARC:UPI0000176903; EMBL:X53342
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IMM>

Query Match 69.4%; Score 59; DB 2; Length 97;
Best Local Similarity 55.0%; Pred. No. 0.0026;
Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

Db 10 SGYYWVWIRQPPGKLEWIG 29

RESULT 11
S26805
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C;Accession: S26805
R;Weng, N.; Snyder, J.G.; Yu-Lee, L.; Marcus, D.M.
Bur. J. Immunol. 22, 1075-1082, 1992
A;Title: Polymorphism of human immunoglobulin V (H) 4 germ-line genes.
A;Reference number: S26800; MUID:92201299; PMID:1348029
A;Accession: S26805
A;Molecule type: DNA
A;Residues: 1-97 WENS
A;Cross-references: UNIPARC:UPI0000116487; EMBL:Z14241; NID:937714; PIDN:CAA78610.1; PIID:1348029
C;Superfamily: immunoglobulin V region; immunoglobulin homology
F;15-97/Domain: immunoglobulin homology <IMM>

Query Match 69.4%; Score 59; DB 2; Length 97;
Best Local Similarity 55.0%; Pred. No. 0.0026;
Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

Db 1 TGYYXXXXQSPEKSLEWIG 20

RESULT 12
S14474
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change 20-Jun-2000
C;Accession: S14474
R;van Es, J.H.; Gmelig Meyling, F.H.J.; van de Akker, W.R.M.; Aanstoot, H.; Derkxen, R.H.
submitted to the EMBL Data Library, November 1990
A;Reference number: S14474
A;Accession: S14474
A;Molecule type: DNA
A;Residues: 1-97 <ESJ>
A;Cross-references: UNIPARC:UPI0000116417; EMBL:X56364
A;Experimental source: UNIPARC:UPI0000116417; EMBL:X56364
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;15-97/Domain: immunoglobulin homology <IMM>

Query Match 69.4%; Score 59; DB 2; Length 97;
Best Local Similarity 55.0%; Pred. No. 0.0026;
Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

Db 30 SGYYWVWIRQPPGKLEWIG 49

RESULT 13
S26806
Ig heavy chain V region - human
C;Species: Homo sapiens (man)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000

Qy 1 TGYXXXXXQSPPEKSLEWIG 20
 S17604 :||| :||| :||| :|||
 Db 30 SGYIWSWIRQQPGKGLEWIG 49

RESULT 13
 Ig heavy chain V region - mouse
 C;Species: Mus musculus (house mouse)
 C;Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 21-Jan-2000
 C;Accession: S17604
 C;Cross-references: UNIPARC:UPI00017604 ; EMBL:X53341
 C;Superfamily: immunoglobulin V region; immunoglobulin homology
 C;Keywords: heterotetramer; immunoglobulin
 F;10-93/Domain: immunoglobulin homology <IMM>

Query Match 69.4%; Score 59; DB 2; Length 110;
 Best Local Similarity 55.0%; Pred. No. 0.0029;
 Matches 11; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPPEKSLEWIG 20
 :||| :||| :||| :|||:
 Db 26 SGYIWSWIRQQPGKGLEWIG 45

Search completed: October 18, 2006, 19:46:48
 Job time : 13.299 secs

Qy 1 TGYXXXXXQSPPEKSLEWIG 20
 :||| :||| :||| :||| :|||:
 Db 23 TGYFMNWVKQSHGKSLEWIG 42

RESULT 14
 S37454 Ig mu chain - human (fragment)
 C;Species: Homo sapiens (man)
 C;Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 23-Jul-1999
 C;Accession: S37454
 R;McIntosh, R.S.; Tandon, N.; Weetman, A.P.
 submitted to the EMBL Data Library, September 1993
 A;Description: Cloning and analysis of human IgM anti-thyroglobulin autoantibodies from
 A;Reference number: S37453
 A;Accession: S37454
 A;Residues: 1-106 <NCI>
 A;Cross-references: UNIPARC:UPI0001161B ; EMBL:X75022; NID:9404311; PIDN:CNAS52930.1; PI
 C;Superfamily: immunoglobulin V region; immunoglobulin homology
 C;Keywords: immunoglobulin

Query Match 69.4%; Score 59; DB 2; Length 106;
 Best Local Similarity 55.0%; Pred. No. 0.0028;
 Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPPEKSLEWIG 20
 :||| :||| :||| :|||:
 Db 8 SGYIWSWIRQQPGKGLEWIG 27

RESULT 15
 S13688 Ig heavy chain V region - mouse (fragment)
 C;Species: Mus musculus (house mouse)
 C;Date: 18-Feb-1994 #sequence_revision 10-Nov-1995 #text_change 30-May-1997
 C;Accession: S13688
 R;Pennell, C.A.; Mercolino, T.J.; Grdina, T.A.; Arnold, L.W.; Haughton, G.; Clarke, S.H.
 Eur. J. Immunol. 19, 1289-1295, 1989
 A;Title: Biased immunoglobulin variable region gene expression by Ly-1 B cells due to cl
 A;Reference number: S13685; PMID:89338557
 A;Accession: S13688
 A;Molecule type: mRNA
 A;Residues: 1-110 <NCI>
 A;Cross-references: UNIPARC:UPI0001161B ; EMBL:X75022; NID:9404311; PIDN:CNAS52930.1; PI

Protein Sequence Searches - February 2005

All of the sequence databases on ABS/S have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.
- If you encounter an accession number from an older search run against UniProt (results file extension .rup) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (UniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.

When submitting sequence search results for scanning into IFW, please include a copy of this attachment to assist any future Examiners or members of the public who may encounter UniProt temporary accession numbers.

Best Available Copy

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: October 18, 2006, 19:11:38 ; Search time 110.309 Seconds
(without alignments)
167.713 Million cell updates/sec

Title: US-10-620-621-1
Perfect score: 85
Sequence: 1 TGYYXXXXQSPBKSKLEWIG 20

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2849598 seqs, 925015592 residues

Total number of hits satisfying chosen parameters:

2849598

RESULT 1
Q65ZRG_MOUSE PRELIMINARY;

ID Q65ZRG;

AC Q65ZRG;

DT 11-OCT-2004;

DT 11-OCT-2004, integrated into UniProtKB/Trembl.

Post-processing: Junctional diversity

0.5

entry version 10.

DB Ab_126.33

heavy chain variable and joining regions (Fragment).

OS Mus musculus (Mouse).

OC Bokaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;

OC Muridae; Murinae; Mus.

OX NCBI_Taxid=10909;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RX MEDLINE=91237115; PubMed=1709665;

RA Rueff-Juy D, Marche P.N., Drapier A.-M., Cazenave P.-A.;

RT "Junctional diversity of H and L chains allows the coexpression of two

RT mutually exclusive idiotypes (Idi104 and Idi1558).";

RL J. Immunol. 146:4024-4030(1991).

CC CC

CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>

CC Distributed under the Creative Commons Attribution-NoDerivs License

CC BMBL: M74139; AAA37776; 1; -; mENA.

DR DR SMR: 0652R6; 18-134.

DR DR Ensembl; ENSMUSG0000057641; Mus musculus.

DR DR InterPro; IPR03599; Ig.

DR DR InterPro; IPR007110; Ig-like.

DR DR InterPro; IPR03596; Ig-V.

DR DR InterPro; IPR013106; V-set.

DR DR SMART; SM00409; Ig; 1.

DR DR SMART; SM04046; IgV; 1.

DR DR Immunglobulin domain.

KW PT PT NON-TER

SEQUENCE 134 AA; 14908 MW; 1852D86D25FC7557 CRC64;

Query Match 76.5%; Score 65; DB 2; Length 134;

Best Local Similarity 65.0%; Pred. No. 0.002;

Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYXXXXQSPBKSKLEWIG 20

Db 47 TDYMMKVKQSPBKSKLEWIG 66

RESULT 2
Q5R3X0_MOUSE PRELIMINARY;

ID Q5R3X0

AC AC

DT 21-DEC-2004, integrated into UniProtKB/Trembl.

DT 21-DEC-2004, sequence version 1.

DT 07-FEB-2006, entry version 8.

Copyright (c) 1993 - 2006 Biocceleration Ltd.	32	54	63.5	101	2	O6b6w2	oryctolagus
	33	54	63.5	102	2	Q6b6u5	oryctolagus
	34	54	63.5	102	2	Q6b6u6	oryctolagus
	35	54	63.5	113	1	P01798	mus musculu
	36	54	63.5	120	2	Q920e8	mus musculu
	37	53	62.4	98	1	P18528	mus musculu
	38	53	62.4	99	2	Q6b6u4	oryctolagus
	39	53	62.4	111	1	P01804	mus musculu
	40	53	62.4	113	1	P01796	mus musculu
	41	53	62.4	113	1	P01797	mus musculu
	42	53	62.4	113	1	HV28	MOUSE
	43	53	62.4	113	1	HV30	MOUSE
	44	53	62.4	113	1	HV31	MOUSE
	45	53	62.4	115	1	HV34	MOUSE
						HV32	MOUSE

ALIGNMENTS

Post-processing: Maximum Match 100%
Listing First 45 summaries

Database : UniProt 7.2:
1: uniprot_sprot:
2: uniprot_trembl:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No. Query Score Match Length DB ID Description

1	65	76.5	134	2	Q65ZRG_MOUSE	0652r6	mus musculu
2	63	74.1	118	2	Q5R3X0_MOUSE	Q5R3x0	mus musculu
3	63	74.1	150	2	Q95973_HUMAN	Q95973	homo sapien
4	63	74.1	470	2	Q7TMK1_MOUSE	Q7tmk1	mus musculu
5	62	72.9	129	1	HV2F_HUMAN	P01824	homo sapien
6	60	70.6	100	1	Q6B6Z2_RABBIT	Q6b6z2	oryctolagus
7	60	70.6	136	1	HV01_XENLA	P20956	xenopus lae
8	59	69.4	119	2	Q9GYZ2_MOUSE	Q9gyz2	mus musculu
9	59	69.4	595	2	QBWKX4_HUMAN	Q8wx4	homo sapien
10	59	69.4	597	2	Q8GMX5_HUMAN	Q6gmx5	homo sapien
11	59	69.4	597	2	Q9BOB8_HUMAN	Q9bqb8	homo sapien
12	59	69.4	597	2	Q9BU10_HUMAN	Q9bu10	homo sapien
13	59	69.4	625	2	Q96AA6_HUMAN	Q96aa6	homo sapien
14	58	68.2	116	2	Q7Z3Y6_HUMAN	Q7z3y6	homo sapien
15	58	68.2	117	1	HV1G_HUMAN	P23093	homo sapien
16	58	68.2	119	2	Q9UL94_HUMAN	Q9u194	homo sapien
17	58	68.2	125	2	Q9UL95_HUMAN	Q9u195	homo sapien
18	57	67.1	117	1	HV41_MOUSE	P01811	mus musculu
19	57	67.1	130	1	Q8IZD7_HUMAN	Q8izd7	homo sapien
20	57	67.1	483	2	Q4VAB6_MOUSE	Q4vab6	mus musculu
21	56	65.9	98	2	Q6B6Z0_RABBIT	Q6b6z0	oryctolagus
22	56	65.9	102	2	Q6B6S8_RABBIT	Q6b6s8	oryctolagus
23	56	65.9	103	2	Q6B713_RABBIT	Q6b713	oryctolagus
24	56	65.9	117	1	HV12_MOUSE	P01756	mus musculu
25	56	65.9	117	1	HV13_MOUSE	P01757	mus musculu
26	56	65.9	117	1	HV17_MOUSE	P01786	mus musculu
27	56	65.9	117	2	Q9QE9_MOUSE	Q9qe9	mus musculu
28	56	65.9	117	2	Q9QXF0_MOUSE	Q9qxf0	mus musculu
29	56	65.9	118	1	HV51_MOUSE	P06330	mus musculu
30	56	65.9	146	1	HV2I_HUMAN	P06331	homo sapien
31	56	65.9	488	2	Q91WR1_MOUSE	Q91wr1	mus musculu

Best Available Copy

RA Strausberg R.; Submitted (AUG-2003) to the EMBL/Genbank/DDBJ databases.

CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>

CC Distributed under the Creative Commons Attribution-NoDerivs License

CC

DR EMBL; BC055910; AAH55910.1; - mRNA.

DR MGI; MGI:2144790; A1324046.

DR Interpro; IPR003599; Ig-like.

DR Interpro; IPR007110; Ig-like.

DR Interpro; IPR003597; Ig_C1.

DR Interpro; IPR003106; Ig_MHC.

DR Interpro; IPR003596; Ig_V.

DR Interpro; IPR013106; V-set.

DR Pfam; PF07554; C1-set; 3.

SMART; SM00409; Ig; 1.

SMART; SM00407; IgC1; 2.

SMART; SM00406; IgV; 1.

PROSITE; PS00835; Ig_LIKE; 4.

DR PROSITE; PS00290; Ig_MHC; UNKNOWN_1.

KW Hypothetical protein.

SEQUENCE 470 AA; 51728 MW; 6D9054DF896BB090 CRC64;

Qy 1 TGYYXXXXXQSPEKSLIEWG 20

Db 49 TGYYMMHNVQSHGKSLEWIG 68

RESULT 5

DR HV2F HUMAN STANDARD; PRT; 129 AA.

AC P01824; Integrated into UniProtKB/Swiss-Prot.

DT 21-JUL-1986, sequence version 1.

DT 21-JUL-1986, entry version 36.

DB Ig heavy chain V-II region WAH.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominoidea; Homo; NCBI_TaxID:9606;

RN [1]

RP PROTEIN SEQUENCE RX MEDLINE=8222235; PubMed=6806818;

RA Takahashi N., Tetaert D., Debuire B., Lin L.-C., Putnam F.W.; "Complete amino acid sequence of the delta heavy chain of human immunoglobulin D," Proc. Natl. Acad. Sci. U.S.A. 79:2850-2854 (1982).

CC -: MISCELLANEOUS: This chain was isolated from an IgD myeloma protein.

CC - SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.

CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>

CC Distributed under the Creative Commons Attribution-NoDerivs License

CC

DR PIR; A02099; DZHUWA.

PDB; 1ZVO; X-ray; C/D=-.

DR SMR; P01824; 2129.

DR GlycosubunitB; P01824; -

DR GO; GO:0005576; C:extracellular region; NAS.

DR GO; GO:0003823; F:antigen binding; NAS.

DR GO; GO:0006955; P:immune response; NAS.

DR InterPro; IPR003599; Ig.

DR InterPro; IPR007110; Ig-like.

DR InterPro; IPR003596; Ig_V.

DR InterPro; IPR013106; V-set.

DR Pfam; PF07686; V-set; 1.

SMART; SM00409; Ig; 1.

DR SMART; SM00406; Ig_LIKE; 4.

DR SMART; SM00835; IgV; 1.

DR SMART; SM00407; IgC1; 2.

DR SMART; SM00409; Ig; 1.

DR PROSITE; PS00290; Ig_MHC; UNKNOWN_1.

KW Immunglobulin V region.

CC CHAIN 1 >129 Ig heavy chain V-II region WAH.

FT DOMAIN 1 113 Ig-like.

FT NON-TER 129 113 MW; D5D53D47ABE51319 CRC64;

SQ SEQUENCE 129 AA; 14117 MW;

Query Match 72.9%; Score 62; DB 1; Length 129;

Best Local Similarity 60.0%; Pred. No. 0.0067;

Matches 12; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1 TGYYXXXXXQSPEKSLIEWG 20

Db 32 TGYYMMHNVQSHGKSLEWIG 51

RESULT 6

DR Q6B6Z2_RABBIT PRELIMINARY; PRT; 100 AA.

AC Q6B6Z2;

DR 13-SEP-2004, integrated into UniProtKB/Trembl.

DT 13-SEP-2004, sequence version 1.

DT 07-FEB-2006, entry version 10.

DE Immunglobulin heavy chain variable region (Fragment).

OS Oryctolagus cuniculus (Rabbit).

OC Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Buteleostomi; Oryctolagus.

OC Mammalia; Eutheria; Euarchontoglires; Glires; Lagomorpha; Leporidae;

OC NCBITaxonID:9986;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RC TRAIN-N New Zealand;

RC SUBMITTED (JUL-2004) to the EMBL/GenBank/DBJ databases.

Qy 1 TGYYXXXXXQSPEKSLIEWG 20

Db 32 TGYYMMHNVQSHGKSLEWIG 51

RESULT 7

DR HV01_XENLA STANDARD; PRT; 136 AA.

ID HV01_XENLA

AC P20956;

DR GO; GO:0005576; C:extracellular region; NAS.

DR GO; GO:0003823; F:antigen binding; NAS.

DR GO; GO:0006955; P:immune response; NAS.

DR InterPro; IPR003599; Ig.

DR InterPro; IPR007110; Ig-like.

DR InterPro; IPR003596; Ig_V.

DR InterPro; IPR013106; V-set.

DR Pfam; PF07686; V-set; 1.

SMART; SM00409; Ig; 1.

DR SMART; SM00406; Ig_LIKE; 4.

DR SMART; SM00407; IgC1; 2.

DR SMART; SM00409; Ig; 1.

DR PROSITE; PS00290; Ig_MHC; UNKNOWN_1.

KW Immunglobulin V region.

CC CHAIN 1 >129 Ig heavy chain V-II region WAH.

FT DOMAIN 1 113 Ig-like.

FT NON-TER 129 113 MW; D5D53D47ABE51319 CRC64;

SQ SEQUENCE 100 AA; 10513 MW;

Query Match 70.6%; Score 60; DB 2; Length 100;

Best Local Similarity 55.0%; Pred. No. 0.012;

Matches 11; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYYXXXXXQSPEKSLIEWG 20

Db 33 SGYMCWVRQADPKGLEWIG 52

RT "Nucleotide sequences of eight human natural autoantibody VH regions
reveals apparent restriction use of VH families.";
J. Immunol. 142:4054-4061(1989).
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
Distributed under the Creative Commons Attribution-NoDerivs License
CC CC BC01235; AAH19235_2; - ; mRNA.
DR PIR; G34954; G34964.
DR HSSP; P01861; IADQ.
DR QBWUK4; 27-256.
DR Ensembl; ENSG00000120076; Homo sapiens.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig_C1.
DR InterPro; IPR003006; Ig_NEC.
DR InterPro; IPR003596; Ig_V.
DR InterPro; IPR013106; V-set.
PFAM; PF07554; Cl-set; 4.
DR SMART; SM00409; Ig; 1.
DR SMART; SM00407; IgC1; 3.
SMART; SM00406; IgV; 1.
PROSITE; PS50835; Ig_LIKE; 5.
DR PROSITE; PS00290; Ig_MHC; UNKNOWN_3.
KW Hypothetical protein.
SQ SEQUENCE 595 AA; 65291 MW; 0D4B50776545714E CRC64;
Query Match Score 59; DB 2; Length 595;
Best Local Similarity 55.0%; Pred. No. 0.13;
Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0.
Qy 1 TGYXXXXXQSPEKSLEWIG 20
Db 56 SGYWSMIRQQPGKGLEWIG 75

RESULT 10
Q6GDX5 HUMAN PRELIMINARY; PRT; 597 AA.
ID Q6GMX5_HUMAN
AC Q6GMX5;
DT 19-JUL-2004; integrated into UniProtKB/TREMBL.
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F., Diatchenko L., Maruskin K., Farmer A.F., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Wagner L., Schuler G.D., Kraus S.S., Loqueland N.A., Peters G.J., Abramson R.D., Mulahay S.J., Bosak S.A., McEvani P.J., McKernan K.J., Malek J.A., Gunnarsson P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villanueva D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A., Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green D., Dickson M.C., Rodriguez A.C., Grifwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E., Schnierch A., Schein J.E., Jones S.J.M., Marra M.A.; "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.";

Best Available Copy

RT	"Generation and initial analysis of more than 15,000 full-length human
RT	and mouse cDNA sequences.";
Proc.	Nat'l. Acad. Sci. U.S.A. 99:16899-16903 (2002).
[2]	
RN	NUCLEOTIDE SEQUENCE
RC	TISSUE-Lymph;
RP	NHGCR Project;
RG	Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases.
RN	[3]
RN	NUCLEOTIDE SEQUENCE
RX	MEDLINE=91252286; PubMed=1904154;
RA	Neale G.A., Kitchingman G.R.
RA	"mRNA transcripts initiating within the human immunoglobulin mu heavy
RT	chain enhancer region contain a non-translatable exon and are
RT	extremely heterogeneous at the 5' end.";
RL	Nucleic Acids Res. 19:2427-2433 (1991).
CC	
CC	Copyrighted by the UniProt Consortium, see http://www.uniprot.org/trembl
CC	Distributed under the Creative Commons Attribution-NoDerivs License
CC	
EMBL; DR	BC017356; AAH17356.2; - ; mRNA.
PIR; S15590;	
HSSP; P01861; 1AQD.	
SMR; Q96A6; 27-256.	
DR	
DR	Ensembl: ENSG00000130076; Homo sapiens
DR	InterPro; IPR03599; Ig.
DR	InterPro; IPR007110; Ig-like.
DR	InterPro; IPR003597; Ig_C1.
DR	InterPro; IPR003006; Ig_MHC.
DR	InterPro; IPR003596; Ig_v.
DR	InterPro; IPR013106; V-set.
Pfam; PF06754; C1-set; 4.	
DR	SMART; SM00409; Ig_1.
DR	SMART; SM00407; IgC1; 3.
SMART; SM00406; IgV_1.	
DR	PROSITE; PS50335; Ig_LIKE; 5.
DR	PROSITE; PS00290; Ig_MHC; UNKNOWN_3.
SQ	SEQUENCE 625 AA; F62FAB3ADE7ECBF6 CRC64;
Score 59; DB 2; Length 625;	
Best Local Similarity 55.0%; Pred. No. 0.14;	
Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps	
Qy	1 TGTYYXXXXQSPEKSLIEWIG 20
Db	: : : : : 75
RESULT 14	
Q723Y6 HUMAN	
ID Q723Y6_HUMAN PRELIMINARY; PRT; 116 AA.	
AC	
DT 01-OCT-2003; integrated into UniProtKB/TremBL.	
DT 01-OCT-2003; sequence version 1.	
DT 07-FEB-2006; entry version 14.	
DE Rearranged VH4-34_v gene segment (Fragment).	
GN Name=VH4-34;	
OS Homo sapiens (Human).	
OC Bathytoye; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;	
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;	
OC Homo	
NCBI_TaxID=9606;	
RN [1] NUCLEOTIDE SEQUENCE.	
RP TISSUE=Hodgkin Lymphoma; RA	
RC Tinsley M.; Rosengurt R.; Sundstroem C.; Amini R.M.; Kuppers R.,	
RA Hansmann M.L.; Brauninger A.;	
RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.	
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/trembl	
CC Distributed under the Creative Commons Attribution-NoDerivs License	
DR EMBL; AJ564425; CAD92032.1; -; Genomic_DNA.	

Copyright (c) 1993 - 2006 Biocceleration Ltd.

OM protein - protein search, using sw model

Run on: October 18, 2006, 19:45:04 ; Search time 24.1237 Seconds
(without alignments)

Perfect score: 85

Title: US-10-620-621-1

Sequence: 1 TGYXXXXQSPEKSLWIG 20

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 650591 seqs, 87530628 residues

Total number of hits satisfying chosen Parameters: 650591

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-Processing: Minimum Match 0%

Maximum Match 100%

Listing First 45 summaries

Database : Issued Patents AA:*

- 1: /EMC_Celerra_SIDS3/prodata/2/iaaa/5_COMB.pep:*
- 2: /EMC_Celerra_SIDS3/prodata/2/iaaa/6_COMB.pep:*
- 3: /EMC_Celerra_SIDS3/prodata/2/iaaa/7_COMB.pep:*
- 4: /EMC_Celerra_SIDS3/prodata/2/iaa/H_COMB.pep:*
- 5: /EMC_Celerra_SIDS3/prodata/2/iaa/PCTUS_COMB.pep:*
- 6: /EMC_Celerra_SIDS3/prodata/2/iaa/RE_COMB.pep:*
- 7: /EMC_Celerra_SIDS3/prodata/2/iaa/backfile1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	80	94.1	20	2 US-08-913-994B-1	Sequence 1, Appli
2	79	92.9	20	2 US-08-913-994B-6	Sequence 6, Appli
3	65	76.5	128	1 US-08-2024-047-21	Sequence 21, Appli
4	65	76.5	128	2 US-08-964-690-21	Sequence 21, Appli
5	63	74.1	93	2 US-09-471-276-821	Sequence 621, App
6	73	74.1	114	1 US-08-888-366-8	Sequence 8, Appli
7	63	74.1	114	2 US-09-724-409-7	Sequence 7, Appli
8	63	74.1	114	2 US-09-724-530-7	Sequence 7, Appli
9	63	74.1	114	2 US-09-296-7	Sequence 7, Appli
10	63	74.1	121	2 US-09-538-705-8	Sequence 8, Appli
11	63	74.1	124	2 US-09-257-069-2	Sequence 2, Appli
12	63	74.1	124	2 US-10-007-790-2	Sequence 2, Appli
13	63	74.1	140	2 US-09-471-276-850	Sequence 850, App
14	63	74.1	222	2 US-09-638-705-13	Sequence 13, Appli
15	63	74.1	243	1 US-08-230-843-4	Sequence 4, Appli
16	63	74.1	243	1 US-08-636-936-4	Sequence 4, Appli
17	60	70.6	116	1 US-08-478-039-79	Sequence 79, Appli
18	60	70.6	116	1 US-08-476-349A-79	Sequence 79, Appli
19	60	70.6	117	2 US-09-744-176A-4	Sequence 4, Appli
20	60	70.6	119	1 US-08-478-039-77	Sequence 77, Appli
21	60	70.6	119	1 US-08-176-349A-77	Sequence 77, Appli
22	60	70.6	137	3 US-09-674-718B-50	Sequence 50, Appli
23	59	69.4	97	2 US-10-194-975-40	Sequence 40, Appli
24	59	69.4	97	2 US-10-194-975-49	Sequence 49, Appli
25	59	69.4	97	2 US-10-194-975-50	Sequence 50, Appli
26	59	69.4	97	2 US-08-896-535-76	Sequence 50, Appli

ALIGNMENTS

RESULT 1
US-08-913-994B-1
; Sequence 1, Application US/08913994B
; Patent No. 6613536
; GENERAL INFORMATION:
; APPLICANT: MOZES, Edna
; WAISMAN, Ari
; TITLE OF INVENTION: SYNTHETIC PEPTIDES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 624 Ninth Street N.W., Ste. 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: United States of America
; ZIP: 20001
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/913,994B
; FILING DATE: 29-SEP-1997
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/04206
; FILING DATE: 27-MAR-1996
; APPLICATION NUMBER: IL 113, 159
; FILING DATE: -MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: BROWDY, Roger L.
; REGISTRATION NUMBER: 25, 618
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; OTHER INFORMATION: /note= Xaa in position 5 is Met, Ala or Val;
Xaa in position 6 is Gln, Asp, Glu, or Arg;
Xaa in position 7 is Trp or Ala;
Xaa in position 8 is Val or Ser;

; and Xaa in position 9 is Lys, Glu or Ala.
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-08-913-994B-1

Query Match Score 80; DB 2; Length 20;
Best Local Similarity 94.1%; Pred. No. 2e-07;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 TGYYYYXXQSPEKSLEWIG 20
Db 1 TGYYYYXXQSPEKSLEWIG 20

RESULT 2
US-08-913-994B-6
Sequence 6, Application US/08913994B

PATENT NO. 613536

GENERAL INFORMATION:

APPLICANT: MOZES, Edna

TITLE OF INVENTION: SYNTHETIC PEPTIDES AND PHARMACEUTICAL
COMPOSITIONS COMPRISING THEM FOR THE TREATMENT
OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

NUMBER OF SEQUENCES: 10

CORRESPONDENCE ADDRESS:

ADDRESSEE: BROWDY AND NEIMARK
CITY: BROWDY AND NEIMARK
STREET: 624 Ninth Street N.W., Ste. 300

CITY: Washington
STATE: D.C.

COUNTRY: United States of America

ZIP: 20001

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/913,994B

FILING DATE: 29-Sep-1997

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/US96/04206

FILING DATE: 27-MAR-1996

APPLICATION NUMBER: IL 113,159

FILING DATE: 28-MAR-1995

ATTORNEY/AGENT INFORMATION:

NAME: BROWDY, Roger L.

REGISTRATION NUMBER: 25,618

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202) 628-1977

TELEFAX: (202) 737-3558

INFORMATION FOR SEQ ID NO: 6:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

SEQUENCE DESCRIPTION: SEQ ID NO: 6:

US-08-913-994B-6

Query Match Score 92.9%; DB 2; Length 20;
Best Local Similarity 75.0%; Pred. No. 3.1e-07;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1 TGYYYYXXQSPEKSLEWIG 20
Db 1 TGYYMWWKQSPGSKSLEWIG 20

RESULT 3
US-08-202-047-21

Sequence 21, Application US/08202047

; Patent No. 5800815
; GENERAL INFORMATION:
; APPLICANT: CHESENBURG, Robert W.
; APPLICANT: POLLEY, Margaret J.
; APPLICANT: PAULSON, James C.
; APPLICANT: JONES, S. Tarran
; APPLICANT: SALDANHA, Jose W.
; APPLICANT: BENDIG, Mary M.
; TITLE OF INVENTION: Antibodies to P-Selectin and Their Uses
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Khourie and Crew
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/202,047
; FILING DATE: 25-FEB-1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 128 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..128
; OTHER INFORMATION: /label= MOUSE_1IA
US-08-202-047-21

; Query Match Score 65; DB 1; Length 128;
; Best Local Similarity 65.0%; Pred. No. 0.0075;
; Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
; Qy 1 TGYYYYXXXXQSPEKSLEWIG 20
; Db 30 TDYYMMWWKQSPGSKSLEWIG 49

; RESULT 4
; US-08-964-690-21
; Sequence 21, Application US/08964690
; ;
; GENERAL INFORMATION:
; ; APPLICANT: CHESENBURG, Robert W.
; ; APPLICANT: POLLEY, Margaret J.
; ; APPLICANT: PAULSON, James C.
; ; APPLICANT: JONES, S. Tarran
; ; APPLICANT: SALDANHA, Jose W.
; ; APPLICANT: BENDIG, Mary M.
; ; TITLE OF INVENTION: Antibodies to P-Selectin and Their Uses
; ; NUMBER OF SEQUENCES: 45
; ; CORRESPONDENCE ADDRESS:
; ; ADDRESSEE: Townsend and Townsend Khourie and Crew
; ; STREET: One Market Plaza, Steuart Tower, Suite 2000
; ; CITY: San Francisco
; ; STATE: California

COUNTRY: USA
 ZIP: 94105
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent in Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/964,690
 FILING DATE:
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/08/202,047
 FILING DATE: 25-FEB-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: Smith, William M.
 REGISTRATION NUMBER: 30,223
 REFERENCE/DOCKET NUMBER: 14137-77
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 415-326-2400
 TELEFAX: 415-326-2422
 INFORMATION FOR SEQ ID NO: 21:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 128 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 FEATURE:
 NAME/KEY: Protein
 LOCATION: 1..128
 OTHER INFORMATION: /label= MOUSE_IA
 US-08-964-690-21

Query Match 76.5%; Score 65; DB 2; Length 128;
 Best Local Similarity 65.0%; Pred. No. 0.00075;
 Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYYYYXXXXQSPEKSLEWIG 20
 Db 30 TDYYMMWKQSGKSLIEWIG 49

RESULT 5
 US-09-471-276-821
 / Sequence 821, Application US/09471276
 / PATENT NO. 6822072
 / GENERAL INFORMATION:
 / APPLICANT: Dumas Milne Edwards, J.B.
 / APPLICANT: Duclert A.
 / APPLICANT: Giordano, J.Y.
 / TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
 / Patent No. 6822072
 / FILE REFERENCE: GENSET 025CP1
 / CURRENT APPLICATION NUMBER: US/09/471,276
 / CURRENT FILING DATE: 1999-12-21
 / EARLIER APPLICATION NUMBER: 9/057,719
 / EARLIER FILING DATE: 1998-04-09
 / EARLIER APPLICATION NUMBER: 9/069,047
 / EARLIER FILING DATE: 1998-04-28
 / EARLIER APPLICATION NUMBER: PCT/IB99/00712
 / NUMBER OF SEQ ID NOS: 1622
 / SOFTWARE: Patent.pm
 / SEQ ID NO. 821
 / LENGTH: 93
 / TYPE: PRT
 / ORGANISM: Homo sapiens
 / FEATURE: SIGNAL
 / LOCATION: -19...-1

US-09-471-276-821

Query Match 74.1%; Score 63; DB 1; Length 114;
 Best Local Similarity 65.0%; Pred. No. 0.0015;
 Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYYYYXXXXQSPEKSLEWIG 20
 Db 24 TGSYMMWKQSGKSLIEWIG 43

RESULT 7
 US-09-724-409-7

Query Match 74.1%; Score 63; DB 1; Length 93;
 Best Local Similarity 65.0%; Pred. No. 0.0012;
 Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYYYYXXXXQSPEKSLEWIG 20
 Db 49 TNYYWSXIROSPCKGLEWIG 68

RESULT 6
 US-08-88-366-8
 / Sequence 8, Application US/0888366
 / Patent No. 5972656
 / GENERAL INFORMATION:
 / APPLICANT: Lopez, Osvaldo
 / APPLICANT: Wylie, Dwane E.
 / APPLICANT: Wagner, Fred W.
 / TITLE OF INVENTION: Mercury Binding Polypeptides and Nucleotides Coding Therefor
 / NUMBER OF SEQUENCES: 39
 / CORRESPONDENCE ADDRESS:
 / ADDRESSEE: Merchant & Gould
 / STREET: 90 South 7th Street, 3100 No. 5972656west Ctr.
 / CITY: Minneapolis
 / STATE: MN
 / COUNTRY: USA
 / ZIP: 55402
 / COMPUTER READABLE FORM:
 / MEDIUM TYPE: Floppy disk
 / COMPUTER: IBM PC compatible
 / OPERATING SYSTEM: PC-DOS/MS-DOS
 / SOFTWARE: PatentIn Release #1.0, Version #1.25
 / CURRENT APPLICATION DATA:
 / APPLICATION NUMBER: US/08/888,366
 / FILING DATE: 03-JUL-1997
 / CLASSIFICATION: 435
 / PRIOR APPLICATION DATA:
 / APPLICATION NUMBER: US 08/187,407
 / FILING DATE: 27-JAN-1994
 / PRIOR APPLICATION DATA:
 / APPLICATION NUMBER: US 07/950,542
 / FILING DATE: 14-DEC-1992
 / PRIOR APPLICATION DATA:
 / APPLICATION NUMBER: US 07/493,299
 / FILING DATE: 14-MAR-1990
 / PRIOR APPLICATION DATA:
 / APPLICATION NUMBER: US 07/324,392
 / FILING DATE: 14-MAR-1989
 / ATTORNEY/AGENT INFORMATION:
 / NAME: Carter, Charles G.
 / REGISTRATION NUMBER: 35,093
 / REFERENCE/DOCKET NUMBER: 8648.39USC1
 / TELECOMMUNICATION INFORMATION:
 / TELEPHONE: 612-332-5300
 / TELEFAX: 612-332-9081
 / INFORMATION FOR SEQ ID NO: 8:
 / SEQUENCE CHARACTERISTICS:
 / LENGTH: 114 amino acids
 / TYPE: amino acid
 / TOPOLOGY: linear
 / MOLECULE TYPE: protein

US-08-88-366-8

```

; Sequence 7, Application US/09724409
; Patent No. 6833261
; GENERAL INFORMATION:
; APPLICANT: Siegall, Clay
; APPLICANT: Wahl, Alan
; APPLICANT: Francisco, Joseph
; APPLICANT: Fell, H. Perry
; TITLE OF INVENTION: RECOMBINANT ANTI-CD40 ANTIBODY AND USES THEREOF
; FILE REFERENCE: 9632-005
; CURRENT APPLICATION NUMBER: US/09/724,409
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US/09/328,296
; PRIOR FILING DATE: 1999-06-08
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 114
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-724-409-7

; RESULT 8
US-09-724-530-7
Query Match 74.1%; Score 63; DB 2; Length 114;
Best Local Similarity 65.0%; Pred. No. 0.0015; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
; GENERAL INFORMATION:
; APPLICANT: Siegall, Clay
; APPLICANT: Wahl, Alan
; APPLICANT: Francisco, Joseph
; APPLICANT: Fell, H. Perry
; TITLE OF INVENTION: RECOMBINANT ANTI-CD40 ANTIBODY AND USES THEREOF
; FILE REFERENCE: 9632-005
; CURRENT APPLICATION NUMBER: US/09/724,530
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: CURRENT APPLICATION NUMBER: US/09/328,296
; PRIOR FILING DATE: CURRENT FILING DATE: 1999-06-08
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 7
; LENGTH: 114
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-724-530-7

; RESULT 9
US-09-328-296-7
Query Match 74.1%; Score 63; DB 2; Length 114;
Best Local Similarity 65.0%; Pred. No. 0.0015; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
; GENERAL INFORMATION:
; APPLICANT: Siegall, Clay
; APPLICANT: Wahl, Alan
; APPLICANT: Francisco, Joseph
; APPLICANT: Fell, H. Perry
; TITLE OF INVENTION: RECOMBINANT ANTI-CD40 ANTIBODY AND USES THEREOF
; FILE REFERENCE: 9632-005
; CURRENT APPLICATION NUMBER: US/09/328,296
; CURRENT FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: JP 1998-252921
; PRIOR FILING DATE: 1998-09-07
; NUMBER OF SEQ ID NOS: 10
; SEQ ID NO 2
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-328-296-7

; RESULT 10
US-09-638-705-8
Query Match 74.1%; Score 63; DB 2; Length 114;
Best Local Similarity 65.0%; Pred. No. 0.0016; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
; GENERAL INFORMATION:
; APPLICANT: Devaux, B.
; APPLICANT: Kellier, G.
; APPLICANT: Koeppen, H.
; APPLICANT: Lasley, L.
; TITLE OF INVENTION: Anti-Tumor Antibody Compositions and Methods of Use
; FILE REFERENCE: PI777R1
; CURRENT APPLICATION NUMBER: US/09/698,705
; CURRENT FILING DATE: 2000-10-27
; PRIOR APPLICATION NUMBER: US 60/162,558
; PRIOR FILING DATE: 1999-10-29
; PRIOR APPLICATION NUMBER: US 60/182,872
; PRIOR FILING DATE: 2000-02-16
; NUMBER OF SEQ ID NOS: 25
; SEQ ID NO 8
; LENGTH: 121
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-638-705-8

; RESULT 11
US-09-257-069-2
Query Match 74.1%; Score 63; DB 2; Length 121;
Best Local Similarity 65.0%; Pred. No. 0.0016; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
; GENERAL INFORMATION:
; APPLICANT: Medical & Biological Laboratories Co.,Ltd.
; TITLE OF INVENTION: Monoclonal Antibody Specific for Phorbolylinostat-3,4,5-Triphosphate
; FILE REFERENCE: M3 -008-US
; CURRENT APPLICATION NUMBER: US/09/257,069
; CURRENT FILING DATE: 1998-02-24
; PRIOR APPLICATION NUMBER: JP 1998-252921
; PRIOR FILING DATE: 1998-09-07
; NUMBER OF SEQ ID NOS: 10
; SEQ ID NO 2
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-257-069-2

; RESULT 12
US-09-257-069-3
Query Match 74.1%; Score 63; DB 2; Length 114;
Best Local Similarity 65.0%; Pred. No. 0.0015; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
; GENERAL INFORMATION:
; APPLICANT: Siegall, Clay
; APPLICANT: Wahl, Alan
; APPLICANT: Francisco, Joseph
; APPLICANT: Fell, H. Perry
; TITLE OF INVENTION: RECOMBINANT ANTI-CD40 ANTIBODY AND USES THEREOF
; FILE REFERENCE: 9632-005
; CURRENT APPLICATION NUMBER: US/09/328,296
; CURRENT FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: JP 1998-252921
; PRIOR FILING DATE: 1998-09-07
; NUMBER OF SEQ ID NOS: 10
; SEQ ID NO 3
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Mus musculus
US-09-257-069-3

```

Query Match 74.1%; Score 63; DB 2; Length 124;
 Best Local Similarity 65.0%; Pred. No. 0.0016;
 Matches 13; Conservative 0; Mismatches 7; Indels 0;
 Gaps 0;

Qy 1 TGYYYYXXXOSPEKSLEWIG 20
 Db 30 TGYYMHWKVQSHGKSLIEWIG 49

RESULT 12
 US-10-007-790-2
 ; Sequence 2, Application US/10007790
 ; Patent No. 6818408
 ; GENERAL INFORMATION:
 ; APPLICANT: Medical & Biological Laboratories Co., Ltd.
 ; TITLE OF INVENTION: Monoclonal Antibody Specific for
 ; FILE REFERENCE: M3-008-US
 ; CURRENT APPLICATION NUMBER: US/10/007,790
 ; CURRENT FILING DATE: 2001-11-13
 ; PRIOR APPLICATION NUMBER: US/09/257,069
 ; PRIORITY FILING DATE: 1999-02-24
 ; PRIOR APPLICATION NUMBER: JP 1998-252921
 ; PRIOR FILING DATE: 1998-09-07
 ; NUMBER OF SEQ ID NOS: 10
 ; SOFTWARE: Patentin Ver. 2.0
 ; SEQ ID NO: 2
 ; LENGTH: 124
 ; TYPE: PRT
 ; ORGANISM: Mus musculus
 ; US-10-007-790-2

Query Match 74.1%; Score 63; DB 2; Length 124;
 Best Local Similarity 65.0%; Pred. No. 0.0016;
 Matches 13; Conservative 0; Mismatches 7; Indels 0;
 Gaps 0;

Qy 1 TGYYYYXXXOSPEKSLEWIG 20
 Db 30 TGYYMHWKVQSHGKSLIEWIG 49

RESULT 13
 US-09-471-276-850
 ; Sequence 850, Application US/09471276
 ; Patent No. 6822072
 ; GENERAL INFORMATION:
 ; APPLICANT: Dumas Milne Edwards, J.B.
 ; DUCLERT A.
 ; APPLICANT: Giordano, J.Y.
 ; TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
 ; PATENT NO. 6822072
 ; FILE REFERENCE: GENSET .025CP1
 ; CURRENT APPLICATION NUMBER: US/09/471,276
 ; CURRENT FILING DATE: 1999-12-21
 ; EARLIER APPLICATION NUMBER: 09/057,719
 ; EARLIER FILING DATE: 1998-04-09
 ; EARLIER APPLICATION NUMBER: 09/069,047
 ; EARLIER FILING DATE: 1998-04-28
 ; EARLIER APPLICATION NUMBER: PCT/IB99/00712
 ; EARLIER FILING DATE: 1999-04-09
 ; NUMBER OF SEQ ID NOS: 1622
 ; SOFTWARE: Patent. pm
 ; SEQ ID NO: 850
 ; LENGTH: 140
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; FEATURE: SIGNAL
 ; NAME/KEY: SIGNAL
 ; LOCATION: -26--1
 ; US-09-471-276-850

Query Match 74.1%; Score 63; DB 2; Length 140;
 Best Local Similarity 63.2%; Pred. No. 0.0019;

Matchee 12; Conservative 0; Mismatches 7; Indels 0;
 Gaps 0;

Qy 2 GTYXXXXXOSPEKSLEWIG 20
 Db 57 GTYIHWVQSHGKSLIEWIG 75

RESULT 14
 US-09-698-705-13
 ; Sequence 13, Application US/09698705
 ; Patent No. 6824180
 ; GENERAL INFORMATION:
 ; APPLICANT: Devaux, B.
 ; APPLICANT: Keller, G.
 ; APPLICANT: Koeppen, H.
 ; APPLICANT: Lasky, L.
 ; TITLE OF INVENTION: Anti-Tumor Antibody Compositions and Methods of Use
 ; FILE REFERENCE: P1777R1
 ; CURRENT APPLICATION NUMBER: US/09/698,705
 ; CURRENT FILING DATE: 2000-10-27
 ; PRIOR APPLICATION NUMBER: US 60/162,558
 ; PRIORITY FILING DATE: 1999-10-29
 ; PRIOR APPLICATION NUMBER: US 60/182,872
 ; PRIORITY FILING DATE: 2000-02-16
 ; NUMBER OF SEQ ID NOS: 25
 ; SEQ ID NO: 13
 ; LENGTH: 222
 ; TYPE: PRT
 ; ORGANISM: Artificial sequence
 ; FEATURE:
 ; OTHER INFORMATION: sequence is chimeric mouse/human
 ; US-09-698-705-13

Query Match 74.1%; Score 63; DB 2; Length 222;
 Best Local Similarity 65.0%; Pred. No. 0.0031;
 Matches 13; Conservative 0; Mismatches 7; Indels 0;
 Gaps 0;

Qy 1 TGYYYYXXXOSPEKSLEWIG 20
 Db 30 GTYIHWVQSHGKSLIEWIG 49

RESULT 15
 US-08-30-843-4
 ; Sequence 4, Application US/08230843
 ; Patent No. 5582826
 ; GENERAL INFORMATION:
 ; APPLICANT: SHIMAMURA, TOSHIRO
 ; APPLICANT: HAMUBO, JUNJI
 ; APPLICANT: NAKAZAWA, HARUMI
 ; APPLICANT: KANAYAMA, YUKA
 ; APPLICANT: SUGAMURA, KAZUO
 ; APPLICANT: TAKESHITA, TOSHIKAZU
 ; TITLE OF INVENTION: IMMUNOSUPPRESSANT
 ; NUMBER OF SEQUENCES: 12
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT,
 ; STREET: 1755 S. Jefferson Davis Highway, Suite 400
 ; CITY: Arlington
 ; STATE: Virginia
 ; COUNTRY: U.S.A.
 ; ZIP: 22202
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patentin Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/230,843
 ; FILING DATE: 21-APR-1994
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:

APPLICATION NUMBER: JP 094491/1993
FILING DATE: 21-APR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 036065/1994
FILING DATE: 07-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Obion, No. 5582526man F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 0010-0674-0X
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 413-3000
TELEFAX: (703) 413-2220
TELEX: 248855 OPAT UR
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 243 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-230-843-4

Query Match 74.1%; Score 63; DB 1; Length 243;
Best Local Similarity 65.0%; Pred. No. 0.0035; Indels 0;
Matches 13; Conservative 0; Mismatches 7; Gaps 0;

Qy 1 TGYYXXXXXOSPEKSLEWIG 20
Db 152 TGYYMEHWVKQSHVKSLEWIG 171

Search completed: October 18, 2006, 19:50:49
Job time : 25.1237 secs

GenCore version 5.1.9	Sequence 19, App1		
Copyright (c) 1993 - 2006 Bioccelerator Ltd.	Sequence 21, App1		
protein - protein search, using sw model	Sequence 66, App1		
on:	Sequence 92, App1		
October 18, 2006, 20:43:15 ; Search time 14.3299 Seconds (without alignments)	Sequence 98, App1		
112.851 Million cell updates/sec	Sequence 110, App1		
file: US-10-620-621-1	Sequence 110, App1		
effect score: 85	Sequence 42, App1		
quence: 1 TGYYYYXXXQSPEKSLEWIG 20	Sequence 13, App1		
oring table: BLOSUM62	Sequence 16, App1		
Gapext 0.5	Sequence 14, App1		
searched: 300827 seqs, 80857/292 residues	Sequence 67, App1		
number of hits satisfying chosen parameters:	Sequence 76, App1		
maximum DB seq length: 0	ALIGNMENTS		
maximum DB seq length: 2000000000			
first processing: Maximum Match 0% Listing first 45 summaries	RESULT 1 US-10-526-741-12 ; Sequence 12, Application US/10526741 ; Publication No. US20060167232A1 ; GENERAL INFORMATION: ; APPLICANT: ABURATANI, Hiroyuki ; APPLICANT: MIDORIKAWA, Yutaka ; APPLICANT: NAKANO, Kiyotaka ; APPLICANT: OHIZUMI, Iwao ; APPLICANT: ITO, Yukio ; APPLICANT: TOKITA, Susumu ; TITLE OF INVENTION: ANTIBODY AGAINST SOLUBLE N-TERMINAL PEPTIDE OR C-TERMINAL PEPTIDE OR C-TERMINAL PEPTIDE ; TITLE OF INVENTION: PRESENT IN BLOOD ; FILE REFERENCE: ; CURRENT APPLICATION NUMBER: US/10/526,741 ; CURRENT FILING DATE: 2005-03-04 ; PRIOR APPLICATION NUMBER: PCT/JP02/08999 ; PRIOR FILING DATE: 2002-09-04 ; NUMBER OF SEQ ID NCS: 24 ; SEQ ID NO: 12 ; LENGTH: 470 ; TYPE: PRT ; ORGANISM: Artificial Sequence ; FEATURE: ; OTHER INFORMATION: Description of Artificial Sequence: Mouse-human ; OTHER INFORMATION: chimeric antibody (MIE07 H chain) US-10-526-741-12		
Published Applications AA_New:*			
1: /EMC_Celerra_SIDS3_prodata/2/_pubpaas/US09 NEW PUB_PEP:*			
2: /EMC_Celerra_SIDS3_prodata/2/_pubpaas/US06 NEW PUB_PEP:*			
3: /EMC_Celerra_SIDS3_prodata/2/_pubpaas/US07 NEW PUB_PEP:*			
4: /EMC_Celerra_SIDS3_prodata/2/_pubpaas/US08 NEW PUB_PEP:*			
5: /EMC_Celerra_SIDS3_prodata/2/_pubpaas/PCT NEW PUB_PEP:*			
6: /EMC_Celerra_SIDS3_prodata/2/_pubpaas/US10 NEW PUB_PEP:*			
7: /EMC_Celerra_SIDS3_prodata/2/_pubpaas/US11 NEW PUB_PEP:*			
8: /EMC_Celerra_SIDS3_prodata/2/_pubpaas/US60 NEW PUB_PEP:*			
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.			
SUMMARIES			
%			
result No.	Score	Query Match Length DB ID	Description
1	79	92.9 470 6 US-10-526-741-12	Sequence 12, App1
2	79	92.9 470 7 US-11-414-676-12	Sequence 12, App1
3	64	75.3 120 7 US-11-221-902-18	Sequence 18, App1
4	64	75.3 447 7 US-11-221-902-18	Sequence 8, App1
5	63	74.1 139 7 US-11-221-902-14	Sequence 14, App1
6	63	74.1 447 7 US-11-221-902-4	Sequence 4, App1
7	63	74.1 447 7 US-11-221-902-6	Sequence 6, App1
8	63	74.1 450 7 US-11-221-902-2	Sequence 2, App1
9	61	71.8 491 7 US-11-293-667-4290	Sequence 4290, App1
10	60	70.6 117 6 US-10-572-226-4	Sequence 4, App1
11	59	69.4 78 1 US-09-784-905-85	Sequence 85, App1
12	59	69.4 92 1 US-09-784-905-86	Sequence 86, App1
13	59	69.4 92 1 US-09-784-905-87	Sequence 87, App1
14	59	69.4 116 7 US-11-241-154-6	Sequence 6, App1
15	59	69.4 124 7 US-11-116-688-55	Sequence 1, App1
16	59	69.4 126 7 US-11-116-688-55	Sequence 55, App1
17	59	69.4 128 7 US-11-094-132-67	Sequence 67, App1
18	59	69.4 139 7 US-11-413-53-2	Sequence 2, App1
19	59	69.4 190 1 US-09-784-905-33	Sequence 33, App1
20	59	69.4 202 1 US-09-784-905-31	Sequence 31, App1
21	59	69.4 205 1 US-09-784-905-23	Sequence 23, App1
22	58	68.2 76 7 US-11-267-880-35	Sequence 35, App1
23	58	68.2 98 7 US-11-221-902-52	Sequence 52, App1
24	58	68.2 98 7 US-11-221-902-52	Sequence 6, App1
25	58	68.2 118 6 US-10-581-300-51	Sequence 51, App1
25	58	68.2 118 6 US-10-581-300-51	Sequence 53, App1
			Sequence 76, App1

APPLICANT: TOKITA, Susumu
TITLE OF INVENTION: ANTIBODY AGAINST SOLUBLE N-TERMINAL PEPTIDE OR C-TERMINAL PEPTIDE
FILE REFERENCE:
CURRENT APPLICATION NUMBER: US/11/414,676
PRIORITY FILING DATE: 2006-04-28
PRIOR APPLICATION NUMBER: US/10/526,741
PRIOR FILING DATE: 2005-11-14
PRIOR FILING DATE: 2002-09-04
NUMBER OF SEQ ID NOS: 24
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 12
LENGTH: 470
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Mouse-human
OTHER INFORMATION: Chimeric antibody (M1E07 H chain)
US-11-414,676-12

Query Match 92.9%; Score 79; DB 7; Length 470;
Best Local Similarity 75.0%; Pred. No. 4.1e-06;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1 TGYYYYXXOSPEKSLEWIG 20
Db 49 TGYYMHWWVKQSPEKSLEWIG 68

RESULT 3
US-11-221-902-18
Sequence 18, Application US/11221902
Publication No. US20060088522A1
GENERAL INFORMATION:
APPLICANT: Wyeth
TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATE
FILE REFERENCE: 0400000-0317285
CURRENT APPLICATION NUMBER: US/11/221,902
CURRENT FILING DATE: 2005-09-09
NUMBER OF SEQ ID NOS: 89
SOFTWARE: Patentin version 3.3
SEQ ID NO 18
LENGTH: 120
TYPE: PRT
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: artificial sequence is derived from mouse and human antibody
OTHER INFORMATION: sequences
US-11-221-902-18

Query Match 75.3%; Score 64; DB 7; Length 120;
Best Local Similarity 60.0%; Pred. No. 0.00046; Indels 7; Mismatches 1; Conservative 1; Gaps 0;

Qy 1 TGYYYYXXOSPEKSLEWIG 20
Db 30 TGYYMHWWVKQSPEKSLEWIG 49

RESULT 4
US-11-221-902-8
Sequence 8, Application US/11221902
Publication No. US20060088522A1
GENERAL INFORMATION:
APPLICANT: Wyeth
TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATE
FILE REFERENCE: 0400000-0317285
CURRENT APPLICATION NUMBER: US/11/221,902
CURRENT FILING DATE: 2005-09-09
NUMBER OF SEQ ID NOS: 89
SOFTWARE: Patentin version 3.3
SEQ ID NO 8

RESULT 5
US-11-221-902-14
Sequence 14, Application US/11221902
Publication No. US20060088522A1
GENERAL INFORMATION:
APPLICANT: Wyeth
TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATE
FILE REFERENCE: 0400000-0317285
CURRENT APPLICATION NUMBER: US/11/221,902
CURRENT FILING DATE: 2005-09-09
NUMBER OF SEQ ID NOS: 89
SOFTWARE: Patentin version 3.3
SEQ ID NO 14
LENGTH: 139
TYPE: PRT
ORGANISM: Mus musculus
FEATURE:
NAME/KEY: MISC_FEATURE
LOCATION: (1)-(19)
OTHER INFORMATION: leader sequence
FEATURE:
NAME/KEY: MATURE_PEPTIDE
LOCATION: (20)-(139)
US-11-221-902-14

Query Match 75.3%; Score 64; DB 7; Length 139;
Best Local Similarity 60.0%; Pred. No. 0.0008; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYYYYXXOSPEKSLEWIG 20
Db 49 TGYYMHWWVKQSPEKSLEWIG 68

RESULT 6
US-11-221-902-4
Sequence 4, Application US/11221902
Publication No. US20060088522A1
GENERAL INFORMATION:
APPLICANT: Wyeth
TITLE OF INVENTION: HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATE
FILE REFERENCE: 0400000-0317285
CURRENT APPLICATION NUMBER: US/11/221,902
CURRENT FILING DATE: 2005-09-09
NUMBER OF SEQ ID NOS: 89
SOFTWARE: Patentin version 3.3
SEQ ID NO 4
LENGTH: 447
TYPE: PRT
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: artificial sequence is derived from mouse and human antibody

OTHER INFORMATION: sequences
 / FEATURE: MISC_FEATURE
 / NAME/KEY: MISC_FEATURE
 / LOCATION: (1..(120)
 ; OTHER INFORMATION: heavy chain variable region
 US-11-221-902-4

Query Match 74.1%; Score 63; DB 7; Length 447;
 Best Local Similarity 65.0%; Pred. No. 0.0028;
 Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYXXXXXQSPEKSLEWIG 20
 Db 30 TGYYMHVKQSHGKSLIEWIG 49

RESULT 9
 US-11-293-697-4290
 ; Sequence 4290, Application US/11293697
 ; Publication No. US20060105376A1

GENERAL INFORMATION:
 / APPLICANT: HELIX RESEARCH INSTITUTE
 / TITLE OF INVENTION: Novel full length cDNA
 / FILE REFERENCE: HI-A0106
 / CURRENT APPLICATION NUMBER: US/11/293,697
 / CURRENT FILING DATE: 2005-12-05
 / PRIORITY APPLICATION NUMBER: US/10/108,260
 / PRIOR FILING DATE: 2002-03-28
 / NUMBER OF SEQ ID NOS: 5458
 / SOFTWARE: PatentIn Ver. 2.1
 / SEQ ID NO: 4290
 / LENGTH: 491
 / TYPE: PRT
 / ORGANISM: Homo sapiens
 US-11-293-697-4290

Query Match 71.8%; Score 61; DB 7; Length 491;
 Best Local Similarity 61.1%; Pred. No. 0.0069;
 Matches 11; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 2 GYXXXXXQSPEKSLEWI 19
 Db 50 GYWWAWIRQSPDKGLEWI 67

RESULT 10
 US-10-972-296-4
 ; Sequence 4, Application US/10972296
 ; Publication No. US200615333A1

GENERAL INFORMATION:
 / APPLICANT: Connex-Gesellschaft zur Optimierung von Forschung und
 / APPLICANT: Entwicklung mbH
 / APPLICANT: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
 / APPLICANT: (I.N.S.E.R.M.)
 / TITLE OF INVENTION: Anti Hepatitis C virus antibody and uses thereof
 / FILE REFERENCE: b3030pc
 / CURRENT APPLICATION NUMBER: US/10/972,296
 / CURRENT FILING DATE: 2004-10-25
 / PRIOR APPLICATION NUMBER: US/09/744,176
 / PRIOR FILING DATE: 2001-07-20
 / PRIORITY APPLICATION NUMBER: ep 98 11 35 95.7
 / PRIOR FILING DATE: 1998-07-21
 / NUMBER OF SEQ ID NOS: 22
 / SOFTWARE: PatentIn version 3.2
 / SEQ ID NO: 4
 / LENGTH: 117
 / TYPE: PRT
 / ORGANISM: Homo sapiens
 US-10-972-296-4

Query Match 70.6%; Score 60; DB 6; Length 117;
 Best Local Similarity 55.0%; Pred. No. 0.0023;
 Matches 11; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYXXXXXQSPEKSLEWIG 20
 Db 30 SGYPTWIRQSPKGLEWIG 49

OTHER INFORMATION: sequences
 / FEATURE: MISC_FEATURE
 / NAME/KEY: MISC_FEATURE
 / LOCATION: (1..(120)
 ; OTHER INFORMATION: heavy chain variable region

```

RESULT 11
US-09-784-950-85
; Sequence 85, Application US/09784950
; PUBLIC INFORMATION:
;   Publication No. US20060104974A1
;   CURRENT APPLICATION NUMBER: US/09/784,950
;   PRIOR APPLICATION NUMBER: PCT/US99/04583
;   PRIOR FILING DATE: 2001-02-15
;   PRIOR APPLICATION NUMBER: 159,03-03
;   PRIOR FILING DATE: 1998-03-03
;   PRIOR APPLICATION NUMBER: 09/034,607
;   PRIOR FILING DATE: 1999-02-03
;   NUMBER OF SEQ ID NOS: 105
;   SOFTWARE: PatentIn Ver. 2.0
;   SEQ ID NO: 85
;   LENGTH: 78
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-784-950-85

Query Match      69.4%; Score 59; DB 1; Length 78;
Best Local Similarity 55.0%; Pred. No. 0.0022; Indels 0; Gaps 0;
Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
Db   11 SGYYWSWIRQPQPGKGLEWIG 30

RESULT 12
US-09-784-950-86
; Sequence 86, Application US/09784950
; PUBLIC INFORMATION:
;   Publication No. US20060104974A1
;   CURRENT APPLICATION NUMBER: US/09/784,950
;   PRIOR APPLICATION NUMBER: PCT/US99/04583
;   PRIOR FILING DATE: 2001-02-15
;   PRIOR APPLICATION NUMBER: 159,03-03
;   PRIOR FILING DATE: 1998-03-03
;   PRIOR APPLICATION NUMBER: 09/034,607
;   PRIOR FILING DATE: 1999-02-03
;   NUMBER OF SEQ ID NOS: 105
;   SOFTWARE: PatentIn Ver. 2.0
;   SEQ ID NO: 87
;   LENGTH: 92
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-784-950-87

Query Match      69.4%; Score 59; DB 1; Length 92;
Best Local Similarity 55.0%; Pred. No. 0.0027; Indels 0; Gaps 0;
Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
Db   11 SGYYWSWIRQPQPGKGLEWIG 30

RESULT 13
US-09-784-950-87
; Sequence 87, Application US/09784950
; Publication No. US20060104974A1
; GENERAL INFORMATION:
;   APPLICANT: Davis, Geoffrey C.
;   APPLICANT: Blacher, Russell W.
;   APPLICANT: Corvalan, Jose R.
;   APPLICANT: Culwell, Alan R.
;   APPLICANT: Green, Larry L.
;   APPLICANT: Hales, Joanna
;   APPLICANT: Havrilla, Nancy
;   APPLICANT: Ivanov, Vladimir E.
;   APPLICANT: Lipani, John A.
;   APPLICANT: Liu, Qiang
;   APPLICANT: Weber, Richard F.
;   APPLICANT: Yang, Xiao-Dong
;   APPLICANT: Abgenix, Inc.
;   APPLICANT: Abgenix, Inc.
;   TITLE OF INVENTION: CD147 BINDING MOLECULES AS THERAPEUTICS
;   FILE REFERENCE: ABX-CBL/CD147
;   CURRENT APPLICATION NUMBER: US/09/784,950
;   CURRENT FILING DATE: 2001-02-15
;   PRIOR APPLICATION NUMBER: PCT/US99/04583
;   PRIOR FILING DATE: 1999-03-03
;   PRIOR APPLICATION NUMBER: 09/034,607
;   PRIOR FILING DATE: 1998-03-03
;   PRIOR APPLICATION NUMBER: 09/244,253
;   PRIOR FILING DATE: 1999-02-03
;   NUMBER OF SEQ ID NOS: 105
;   SOFTWARE: PatentIn Ver. 2.0
;   SEQ ID NO: 85
;   LENGTH: 78
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-784-950-87

Query Match      69.4%; Score 59; DB 1; Length 78;
Best Local Similarity 55.0%; Pred. No. 0.0022; Indels 0; Gaps 0;
Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0;

Qy   1 TGYYXXXXQSPEKSLEWIG 20
Db   11 SGYYWSWIRQPQPGKGLEWIG 30

RESULT 14
US-11-241-154-6
; Sequence 6, Application US/11241154
; Publication No. US2006017442A1
; GENERAL INFORMATION:
;   APPLICANT: Tibor KELER
;   TITLE OF INVENTION: METHOD OF TREATING CD30 POSITIVE LYMPHOMAS
;   FILE REFERENCE: MXI-327
;   CURRENT APPLICATION NUMBER: US/11/241,154
;   CURRENT FILING DATE: 2005-09-30
;   PRIOR APPLICATION NUMBER: 09/034,607
;   PRIOR FILING DATE: 1998-03-03
;   PRIOR APPLICATION NUMBER: 09/244,253
;   PRIOR FILING DATE: 1999-02-03
;   NUMBER OF SEQ ID NOS: 105
;   SOFTWARE: PatentIn Ver. 2.0
;   SEQ ID NO: 87
;   LENGTH: 92
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-11-241-154-6

```

PRIOR APPLICATION NUMBER: 60/615284
 PRIOR FILING DATE: 2004-10-01.
 NUMBER OF SEQ ID NOS: 53
 SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO: 6
 LENGTH: 116
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-11-241-154-6

Query Match Score 59; DB 7; Length 116;
 Best Local Similarity 55.0%; Pred. No. 0.0034;
 Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0;
 Qy 1 TGYYYYXXQSPKSLEWIG 20
 :||| :||| :||| :|||
 Db 30 SGTYWSWRQQPKGLEWIG 49

RESULT 15
 US-11-111-688-1
 Sequence 1, Application US/11111688
 Publication No. US20060115486A1
 GENERAL INFORMATION
 APPLICANT: Pier, Gerald B
 APPLICANT: Kelly-Quintos, Casie A
 APPLICANT: Cavacini, Lisa
 APPLICANT: Rosner, Marshall R
 TITLE OF INVENTION POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG) - BINDING
 PEPTIDES AND METHODS OF USE THEREOF
 FILE REFERENCE: B0801.703000US01
 CURRENT APPLICATION NUMBER: US/11/111,688
 CURRENT FILING DATE: 2005-04-21
 PRIOR APPLICATION NUMBER: US 60/564,105
 PRIOR FILING DATE: 2004-04-21
 NUMBER OF SEQ ID NOS: 61
 SOFTWARE: PatentIn version 3.3
 SEQ ID NO: 1
 LENGTH: 124
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-11-111-688-1

Query Match Score 59; DB 7; Length 124;
 Best Local Similarity 55.0%; Pred. No. 0.0037;
 Matches 11; Conservative 1; Mismatches 8; Indels 0; Gaps 0;
 Qy 1 TGYYYYXXQSPKSLEWIG 20
 :||| :||| :||| :|||
 Db 30 SGTYWSWRQQPKGLEWIG 49

Search completed: October 18, 2006, 20:58:14
 Job time : 14.3299 sees

GenCore version 5.1.9
 Copyright (c) 1993 - 2006 Bioccelleration Ltd.

OM protein - protein search, using sw model

Run on: October 18, 2006, 19:47:09 ; Search time 294.33 Seconds

(without alignments) 103.758 Million cell updates/sec

Title: US-10-620-621-1
 Perfect score: 85
 Sequence: 1 TGYXXXXXQSPEKSLIEWIG 20

Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 8366291 seqs, 1526956180 residues

Total number of hits satisfying chosen parameters:

8366291

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0 %

Maximum Match 100 %

Listing First 45 summaries

Database : Pending_Patents_AA_Main:*

Result No.	Score	Query Match	Length	DB ID	Description
1	80	94.1	20	1 PCT-US96-04206-1	Sequence 1, Appli
2	80	94.1	20	36 US-10-620-621-1	Sequence 1, Appli
3	80	94.1	20	37 US-10-758-397-11	Sequence 11, Appli
4	80	94.1	20	37 US-10-758-397A-11	Sequence 11, Appli
5	79	92.9	20	1 PCT-IL02-00148-1	Sequence 1, Appli
6	79	92.9	20	1 PCT-US96-04206-6	Sequence 6, Appli
7	79	92.9	20	34 US-10-460-924-1	Sequence 1, Appli
8	79	92.9	20	34 US-10-468-924A-1	Sequence 1, Appli
9	79	92.9	20	36 US-10-620-621-6	Sequence 6, Appli
10	79	92.9	20	37 US-10-758-397-1	Sequence 1, Appli
11	79	92.9	20	37 US-10-758-397B-1	Sequence 1, Appli
12	79	92.9	103	27 US-0-791-537-11946	Sequence 11946, A
13	79	92.9	105	27 US-0-791-537-82724	Sequence 82724, A
14	79	92.9	111	27 US-0-791-537-14790	Sequence 14790, A
15	79	92.9	112	27 US-0-791-537-14835	Sequence 14835, A
16	79	92.9	115	27 US-0-791-537-14831	Sequence 14831, A
17	79	92.9	118	27 US-0-791-537-149906	Sequence 149906,
18	79	92.9	138	27 US-0-791-537-77301	Sequence 77301, A
19	79	92.9	470	35 US-10-56-741-12	Sequence 12, Appli
20	74	87.1	97	27 US-0-791-537-61187	Sequence 61187, A
21	71	83.5	255	1 PCT-US01-19110-1626	Sequence 1626, Ap
22	71	83.5	255	1 PCT-US02-6494-1626	Sequence 1626, Ap
23	71	83.5	255	28 US-0-880-748-1626	Sequence 1626, Ap
24	71	83.5	255	32 US-10-293-418-1626	Sequence 1626, Ap
25	71	83.5	255	40 US-11-056-1626	Sequence 1626, Ap
26	71	83.5	255	42 US-11-26-444-1626	Sequence 1626, Ap
27	71	83.5	255	52 US-6-725-626-1626	Sequence 1626, Ap
28	71	83.5	255	52 US-0-735-665-1626	Sequence 1626, Ap
29	71	83.5	255	52 US-6-0-776-665-1626	Sequence 1626, Ap
30	71	83.5	467	39 US-10-961-567A-3	Sequence 3, Appli
31	71	83.5	255	42 US-11-056-1626	Sequence 1626, Ap
32	70	82.4	119	27 US-0-791-537-135207	Sequence 135207,
33	68	80.0	671	42 US-11-202-507A-14	Sequence 14, Appli
34	68	80.0	672	29 US-0-900-766-1	Sequence 1, Appli
35	68	80.0	672	42 US-11-202-507A-7	Sequence 7, Appli
36	67	78.8	117	27 US-0-791-537-129898	Sequence 129898,
37	65	76.5	89	27 US-0-791-537-72370	Sequence 72370, A
38	65	76.5	97	27 US-0-791-537-144799	Sequence 144799,
39	65	76.5	106	27 US-0-791-537-6277	Sequence 6277, Ap
40	65	76.5	115	27 US-0-791-537-102697	Sequence 102697,
41	65	76.5	117	27 US-0-791-537-41128	Sequence 41128,
42	65	76.5	129	33 US-10-312-6-47	Sequence 47, Appli
43	65	76.5	134	27 US-0-791-537-22034	Sequence 22034, A
44	65	76.5	134	27 US-0-791-537-22035	Sequence 22035, A
45	65	76.5	134	27 US-0-791-537-22040	Sequence 22040, A

SUMMARIES

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the total score distribution and is derived by analysis of the total score distribution.

BLOSUM62

Result No.	Score	Query Match	Length	DB ID	Description
1	80	94.1	20	1 PCT-US96-04206-1	Sequence 1, Appli
2	80	94.1	20	36 US-10-620-621-1	Sequence 1, Appli
3	80	94.1	20	37 US-10-758-397-11	Sequence 11, Appli
4	80	94.1	20	37 US-10-758-397A-11	Sequence 11, Appli
5	79	92.9	20	1 PCT-IL02-00148-1	Sequence 1, Appli
6	79	92.9	20	1 PCT-US96-04206-6	Sequence 6, Appli
7	79	92.9	20	34 US-10-460-924-1	Sequence 1, Appli
8	79	92.9	20	34 US-10-468-924A-1	Sequence 1, Appli
9	79	92.9	20	36 US-10-620-621-6	Sequence 6, Appli
10	79	92.9	20	37 US-10-758-397B-1	Sequence 1, Appli
11	79	92.9	103	27 US-0-791-537-11946	Sequence 11946, A
12	79	92.9	111	27 US-0-791-537-82724	Sequence 82724, A
13	79	92.9	112	27 US-0-791-537-14790	Sequence 14790, A
14	79	92.9	115	27 US-0-791-537-14835	Sequence 14835, A
15	79	92.9	116	27 US-0-791-537-14831	Sequence 14831, A
16	79	92.9	118	27 US-0-791-537-149906	Sequence 149906,
17	79	92.9	118	27 US-0-791-537-77301	Sequence 77301, A
18	79	92.9	138	27 US-0-791-537-72370	Sequence 72370, A
19	79	92.9	470	35 US-10-56-741-12	Sequence 12, Appli
20	74	87.1	97	27 US-0-791-537-61187	Sequence 61187, A
21	71	83.5	255	1 PCT-US01-19110-1626	Sequence 1626, Ap
22	71	83.5	255	1 PCT-US02-6494-1626	Sequence 1626, Ap
23	71	83.5	255	28 US-0-880-748-1626	Sequence 1626, Ap
24	71	83.5	255	32 US-10-293-418-1626	Sequence 1626, Ap
25	71	83.5	255	40 US-11-056-1626	Sequence 1626, Ap
26	71	83.5	255	42 US-11-26-444-1626	Sequence 1626, Ap
27	71	83.5	255	52 US-6-725-626-1626	Sequence 1626, Ap
28	71	83.5	255	52 US-0-735-665-1626	Sequence 1626, Ap
29	71	83.5	255	52 US-6-0-776-665-1626	Sequence 1626, Ap
30	71	83.5	467	39 US-10-961-567A-3	Sequence 3, Appli
31	71	83.5	255	42 US-11-056-1626	Sequence 1626, Ap
32	70	82.4	119	27 US-0-791-537-135207	Sequence 135207,
33	68	80.0	671	42 US-11-202-507A-14	Sequence 14, Appli
34	68	80.0	672	29 US-0-900-766-1	Sequence 1, Appli
35	68	80.0	672	42 US-11-202-507A-7	Sequence 7, Appli
36	67	78.8	117	27 US-0-791-537-129898	Sequence 129898,
37	65	76.5	89	27 US-0-791-537-72370	Sequence 72370, A
38	65	76.5	97	27 US-0-791-537-144799	Sequence 144799,
39	65	76.5	106	27 US-0-791-537-6277	Sequence 6277, Ap
40	65	76.5	115	27 US-0-791-537-102697	Sequence 102697,
41	65	76.5	117	27 US-0-791-537-41128	Sequence 41128,
42	65	76.5	129	33 US-10-312-6-47	Sequence 47, Appli
43	65	76.5	134	27 US-0-791-537-22034	Sequence 22034, A
44	65	76.5	134	27 US-0-791-537-22035	Sequence 22035, A
45	65	76.5	134	27 US-0-791-537-22040	Sequence 22040, A

ALIGNMENTS

RESULT 1
 PCT-US6-04206-1
 Sequence 1, Application PC/TUS9604206
 ; GENERAL INFORMATION:
 ; GENERAL INFORMATION:

PCT-IL02-00148-1
 Query Match 92.9%; Score 79; DB 1; Length 20;
 Best Local Similarity 75.0%; Pred. No. 3.6e-06;
 Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPKSLEWIG 20
 Db 1 TGYYXXXXQSPKSLEWIG 20

RESULT 4
 US-10-758-397A-11
 ; Sequence 11, Application US/10758397A

GENERAL INFORMATION:
 APPLICANT: Cohen-Vered, et al., Sharon

TITLE OF INVENTION: PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC ERYTHEMATOSUS

CURRENT APPLICATION NUMBER: US/10/758.397A
 CURRENT FILING DATE: 2004-01-14
 NUMBER OF SEQ ID NOS: 18
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO 11
 LENGTH: 20
 TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:
 OTHER INFORMATION: Synthetic peptide based on CDR of mouse autoantibody

FEATURE:
 NAME/KEY: MISC_FEATURE
 LOCATION: (5)...(5)

OTHER INFORMATION: X= Met, Ala or Val

FEATURE:
 NAME/KEY: MISC_FEATURE
 LOCATION: (6)...(6)

OTHER INFORMATION: X= Gln, Asp, Glu or Arg

FEATURE:
 NAME/KEY: MISC_FEATURE
 LOCATION: (7)...(7)

OTHER INFORMATION: X= Trp or Ala

FEATURE:
 NAME/KEY: MISC_FEATURE
 LOCATION: (8)...(8)

OTHER INFORMATION: X= Val or Ser

FEATURE:
 NAME/KEY: MISC_FEATURE
 LOCATION: (9)...(9)

OTHER INFORMATION: X= Lys, Glu or Ala

US-10-758-397A-11

Query Match 94.1%; Score 80; DB 37; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.4e-06;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TGYYYYXXQSPKSLEWIG 20
 Db 1 TGYYYYXXQSPKSLEWIG 20

RESULT 5
 PCT-IL02-00148-1
 Sequence 1, Application PC/IL02/00148

GENERAL INFORMATION:
 APPLICANT: YEDA Research and Development Co. Ltd

TITLE OF INVENTION: PEPTIDES FROM THE 16/6id ANTIBODY FOR TREATING SLE

FILE REFERENCE: TEVA-003 PCT
 CURRENT APPLICATION NUMBER: PCT/IL02/00148
 CURRENT FILING DATE: 2003-10-15
 PRIOR APPLICATION NUMBER: IL 141647
 PRIOR FILING DATE: 2001-02-26
 NUMBER OF SEQ ID NOS: 30
 SEQ ID NO 1
 LENGTH: 20
 TYPE: PRT
 ORGANISM: Murine

Query Match 92.9%; Score 79; DB 34; Length 20;
 Best Local Similarity 75.0%; Pred. No. 3.6e-06;

Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0; Title of Invention: METHODS OF USE THEREOF
 Query 1 TGYYXXXXQSPKSLIEWIG 20 File Reference: 261/210
 Db 1 TGYYMWTQSPKSLIEWIG 20 Current Application Number: US/09/791,537
 ; CURRENT FILING DATE: 2001-02-22
 ; NUMBER OF SEQ ID NOS: 153055
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO: 14790
 ; LENGTH: 111
 ; TYPE: PRT
 ; ORGANISM: Mus musculus

RESULT 12 US-09-791-537-11946
 Sequence 11946, Application US/09791537
 ; GENERAL INFORMATION
 ; APPLICANT: Bionomix, Inc.
 ; APPLICANT: Debe, Derek
 ; APPLICANT: Danzer, Joseph
 ; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBER
 ; FILE REFERENCE: 261/210
 ; CURRENT APPLICATION NUMBER: US/09/791,537
 ; CURRENT FILING DATE: 2001-02-22
 ; NUMBER OF SEQ ID NOS: 153055
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO: 11946
 ; LENGTH: 103
 ; TYPE: PRT
 ; ORGANISM: Mus musculus

Query Match 92.9%; Score 79; DB 27; Length 111;
 Best Local Similarity 75.0%; Pred. No. 1.9e-05;
 Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPKSLIEWIG 20
 Db 26 TGYYMWTQSPKSLIEWIG 45

RESULT 15 US-09-791-537-14835
 Sequence 14835, Application US/09791537
 ; GENERAL INFORMATION
 ; APPLICANT: Bionomix, Inc.
 ; APPLICANT: Debe, Derek
 ; APPLICANT: Danzer, Joseph
 ; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBER
 ; FILE REFERENCE: 261/210
 ; CURRENT APPLICATION NUMBER: US/09/791,537
 ; CURRENT FILING DATE: 2001-02-22
 ; NUMBER OF SEQ ID NOS: 153055
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO: 14835
 ; LENGTH: 112
 ; TYPE: PRT
 ; ORGANISM: Mus musculus

Query Match 92.9%; Score 79; DB 27; Length 112;
 Best Local Similarity 75.0%; Pred. No. 1.9e-05;
 Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPKSLIEWIG 20
 Db 27 TGYYMWTQSPKSLIEWIG 46

Search completed: October 18, 2006, 20:38:32
 Job time : 295.33 secs

RESULT 13 US-09-791-537-82724
 Sequence 82724, Application US/09791537
 ; GENERAL INFORMATION
 ; APPLICANT: Bionomix, Inc.
 ; APPLICANT: Debe, Derek
 ; APPLICANT: Danzer, Joseph
 ; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBER
 ; FILE REFERENCE: 261/210
 ; CURRENT APPLICATION NUMBER: US/09/791,537
 ; CURRENT FILING DATE: 2001-02-22
 ; NUMBER OF SEQ ID NOS: 153055
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO: 82724
 ; LENGTH: 105
 ; TYPE: PRT
 ; ORGANISM: Mus musculus

Query Match 92.9%; Score 79; DB 27; Length 105;
 Best Local Similarity 75.0%; Pred. No. 1.8e-05;
 Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1 TGYYXXXXQSPKSLIEWIG 20
 Db 29 TGYYMWTQSPKSLIEWIG 48

RESULT 14 US-09-791-537-14790
 Sequence 14790, Application US/09791537
 ; GENERAL INFORMATION
 ; APPLICANT: Bionomix, Inc.
 ; APPLICANT: Debe, Derek
 ; APPLICANT: Danzer, Joseph
 ; TITLE OF INVENTION: THREE DIMENSIONAL STRUCTURES OF PROTEIN FAMILIES AND FAMILY MEMBER

November 2005

Published_Applications Nucleic Acid and Published_Applications Amino Acid database searches now generate two sets of results each. The Published_Applications databases have been split into two parts to reduce the amount of time required for their daily updates. This results in more machine time being available for processing searches.

Newly published applications will appear in the Published_Applications_New databases; older published applications make up the Published_Applications_Main database's.

Searches run against Nucleic Acid Published_Applications produce two sets of results, with the extensions .rnpbm (Published_Applications_NA_Main) and .rnpbn (Published_Applications_NA_New).

Searches run against Amino Acid Published_Applications produce two sets of results, with the extensions .rapbm (Published_Applications_AA_Main) and .rapbn (Published_Applications_AA_New).

US-11-202-507A-14

Query Match 80.0%; Score 68; DB 6; Length 671;
Best Local Similarity 65.0%; Pred. No. 0.0072; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYYXXXXXOSPEKSLEWIG 20
Db 30 TGYMMHWRQSPGKLEWIG 49

Query Match 80.0%; Score 68; DB 6; Length 672;
Best Local Similarity 65.0%; Pred. No. 0.0072; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 1 TGYYXXXXXOSPEKSLEWIG 20
Db 30 TGYMMHWRQSPGKLEWIG 49

RESULT 15
US-10-12-316-47

; Sequence 47, Application US/10312316
; Publication No. US20040137513A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; APPLICANT: Devaux, Brigitte S.
; APPLICANT: Hongo, Jo-Anne S.
; APPLICANT: Presta, Leonard G.
; APPLICANT: Shelton, David L.
; TITLE OF INVENTION: AGONIST ANTI-TRK-C MONOCLONAL ANTIBODIES
; FILE REFERENCE: GENENT 040QPC
; CURRENT APPLICATION NUMBER: US/10/312,316
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: 60/238,319
; PRIOR FILING DATE: 2000-10-05
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 47
; LENGTH: 129
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-12-316-47

Query Match 76.5%; Score 65; DB 4; Length 129;
Best Local Similarity 63.2%; Pred. No. 0.0045; Indels 0; Gaps 0;

Matches 12; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 2 TGYYXXXXXOSPEKSLEWIG 20
Db 34 GYYWSWIKHPERGLEWIG 52

Search completed: October 18, 2006, 20:55:48
Job time : 80.3814 secs

RESULT 14
US-11-202-507A-7

; Sequence 7, Application US/11202507A
; Publication No. US20060057111A1
; GENERAL INFORMATION:
; APPLICANT: Hedlund, Gunnar
; APPLICANT: Forsberg, Goran
; APPLICANT: Wallen Ohman, Marie
; TITLE OF INVENTION: TREATMENT OF HYPERPROLIFERATIVE DISEASE WITH SUPERANTIGENS IN
; TITLE OF INVENTION: COMBINATION WITH ANOTHER ANTICANCER AGENT
; FILE REFERENCE: P01024US1
; CURRENT APPLICATION NUMBER: US/11/202,507A
; CURRENT FILING DATE: 2005-08-12
; PRIOR APPLICATION NUMBER: US 60/601,548
; PRIOR FILING DATE: 2004-08-13
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 7
; LENGTH: 672
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE: Conjugate Protein
; OTHER INFORMATION: Conjugate Protein
; NAME/KEY: MISC FEATURE
; LOCATION: (449) .. (672)
; OTHER INFORMATION: Light Chain
US-11-202-507A-7

PRIOR FILING DATE: 2000-10-17
 Remaining Prior Application data removed - See File Wrapper or PALM.
 NUMBER OF SEQ ID NOS: 3247
 SEQ ID NO 1626
 LENGTH: 255
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-11-054-515-1626

Query Match Score 71; DB 6; Length 255;
 Best Local Similarity 65.0%; Pred. No. 0.00083;
 Matches 13; Conservative 1; Mismatches 6; Indels 0;
 Gaps 0;
 Qy 1 TGYYXXXXQSPEKSLEWIG 20
 Db 30 SGYYNSWRQSPKGGLEWIG 49

RESULT 9
 US-11-266-444-1626
 Sequence 1626, Application US/11266444
 Publication No. US2006062789A1
 GENERAL INFORMATION:
 APPLICANT: Ruben et al.
 TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulatory Factor Reference: PF523P1D1
 CURRENT APPLICATION NUMBER: US/11/266,444
 CURRENT FILING DATE: 2005-11-04
 PRIOR APPLICATION NUMBER: 09-880,746
 PRIOR FILING DATE: 2001-06-15
 PRIOR APPLICATION NUMBER: 60/212,210
 PRIOR FILING DATE: 2000-06-16
 PRIOR APPLICATION NUMBER: 60/240,816
 PRIOR FILING DATE: 2000-10-17
 PRIOR APPLICATION NUMBER: 60/276,248
 PRIOR FILING DATE: 2001-03-16
 PRIOR APPLICATION NUMBER: 60/277,379
 PRIOR FILING DATE: 2001-03-21
 PRIOR APPLICATION NUMBER: 60/293,499
 PRIOR FILING DATE: 2001-05-25
 NUMBER OF SEQ ID NOS: 3239
 SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO 1626
 LENGTH: 255
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-11-266-444-1626

Query Match Score 71; DB 6; Length 255;
 Best Local Similarity 65.0%; Pred. No. 0.00083;
 Matches 13; Conservative 1; Mismatches 6; Indels 0;
 Gaps 0;
 Qy 1 TGYYXXXXQSPEKSLEWIG 20
 Db 30 SGYYNSWRQSPKGGLEWIG 49

RESULT 10
 US-10-961-567A-3
 Sequence 3, Application US/10961567A
 Publication No. US2005009524A1
 GENERAL INFORMATION:
 APPLICANT: Jure-Kunkel, Maria
 APPLICANT: Hefts, Laura
 APPLICANT: Santoro, Marc
 APPLICANT: Ganguly, Subinay
 TITLE OF INVENTION: FULLY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB
 FILE REFERENCE: 10060 NP
 CURRENT APPLICATION NUMBER: US/10/961,567A
 CURRENT FILING DATE: 2004-10-08
 PRIOR APPLICATION NUMBER: US 60/510193
 PRIOR FILING DATE: 2003-10-10
 NUMBER OF SEQ ID NOS: 9
 SOFTWARE: PatentIn version 3.2
 SEQ ID NO 9
 LENGTH: 470
 TYPE: PRT
 ORGANISM: Artificial
 FEATURE:
 OTHER INFORMATION: 20H4-9-IgG1 amino acid sequence

RESULT 11
 US-10-961-567A-9
 Sequence 9, Application US/10961567A
 Publication No. US2005009524A1
 GENERAL INFORMATION:
 APPLICANT: Jure-Kunkel, Maria
 APPLICANT: Hefts, Laura
 APPLICANT: Santoro, Marc
 APPLICANT: Ganguly, Subinay
 TITLE OF INVENTION: FULLY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB
 FILE REFERENCE: 10060 NP
 CURRENT APPLICATION NUMBER: US/10/961,567A
 CURRENT FILING DATE: 2004-10-08
 PRIOR APPLICATION NUMBER: US 60/510193
 PRIOR FILING DATE: 2003-10-10
 NUMBER OF SEQ ID NOS: 9
 SOFTWARE: PatentIn version 3.2
 SEQ ID NO 9
 LENGTH: 470
 TYPE: PRT
 ORGANISM: Artificial
 FEATURE:
 OTHER INFORMATION: 20H4-9-IgG1 amino acid sequence

RESULT 12
 US-11-202-507A-14
 Sequence 14, Application US/11202507A
 Publication No. US2006005711A1
 GENERAL INFORMATION:
 APPLICANT: Hedlund, Gunnar
 APPLICANT: Forssberg, Goran
 APPLICANT: Wallen-Oman, Marie
 TITLE OF INVENTION: TREATMENT OF HYPERPROLIFERATIVE DISEASE WITH SUPERANTIGENS IN COMBINATION WITH ANOTHER ANTICANCER AGENT
 FILE REFERENCE: P03024US1
 CURRENT APPLICATION NUMBER: US/11/202,507A
 CURRENT FILING DATE: 2005-08-12
 PRIOR APPLICATION NUMBER: US 60/601,548
 PRIOR FILING DATE: 2004-08-13
 NUMBER OF SEQ ID NOS: 16
 SOFTWARE: PatentIn version 3.3
 SEQ ID NO 14
 LENGTH: 671
 TYPE: PRT
 ORGANISM: staphylococcus sp

